



(86) Date de dépôt PCT/PCT Filing Date: 2003/06/05
(87) Date publication PCT/PCT Publication Date: 2003/12/18
(45) Date de délivrance/Issue Date: 2011/07/05
(85) Entrée phase nationale/National Entry: 2004/12/06
(86) N° demande PCT/PCT Application No.: EP 2003/005929
(87) N° publication PCT/PCT Publication No.: 2003/104282
(30) Priorité/Priority: 2002/06/07 (EP02 012 742.9)

(51) Cl.Int./Int.Cl. *C07K 19/00* (2006.01),
A61K 47/48 (2006.01), *A61P 7/02* (2006.01),
C07K 14/705 (2006.01), *C07K 16/28* (2006.01),
C12N 15/62 (2006.01), *G01N 33/50* (2006.01),
G01N 33/53 (2006.01), *G01N 33/86* (2006.01),
A61K 38/00 (2006.01)

(72) Inventeurs/Inventors:
MASSBERG, STEFFEN, DE;
GAWAZ, MEINRAD, DE;
BUELTSMANN, ANDREAS, DE;
MUENCH, GOETZ, DE;
UNGERER, MARTIN, DE;
PELUSO, MARIO, DE

(73) Propriétaire/Owner:

(54) Titre : IMMUNOADHESINE CONTENANT LE DOMAINE DE LA GLYCOPROTEINE VI
(54) Title: IMMUNOADHESIN COMPRISING A GLYCOPROTEIN VI DOMAIN

(57) **Abrégé/Abstract:**

The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in Figure 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.

(73) Propriétaires(suite)/Owners(continued):CORIMMUN GMBH, DE

(74) Agent: SMART & BIGGAR

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 2003/104282 A3

(51) International Patent Classification⁷: **C07K 19/00**,
C12N 15/62, G01N 33/53, A61P 7/02

(21) International Application Number:
PCT/EP2003/005929

(22) International Filing Date: 5 June 2003 (05.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02 012 742.9 7 June 2002 (07.06.2002) EP

(71) Applicant (*for all designated States except US*): **PRO-CORDE GMBH** [DE/DE]; Fraunhoferstr. 9, 82152 Martinsried (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MASSBERG, Steffen** [DE/DE]; Ridlerstr. 29b, 80339 München (DE). **GAWAZ, Meinrad** [DE/DE]; Osterwaldstr. 129, 80805 München (DE). **BÜLTMANN, Andreas** [DE/DE]; Claude-Lorrain Str. 25, 81543 München (DE). **MÜNCH, Götz** [DE/DE]; Schellingstr. 23, 80799 München (DE). **UNGERER, Martin** [DE/DE]; Georgenstr. 57, 80799 München (DE). **PELUSO, Mario** [DE/DE]; Fischhaberstr. 13, 82377 Penzberg (DE).

(74) Agent: **HARTZ, Nikolai**; Wächtershäuser & Hartz, European Patent and Trademark Attorneys, Weinstrasse 8, 80333 München (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
14 October 2004

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 18/2004 of 29 April 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GLYCOPROTEIN VI - FC FUSION PROTEIN FOR TREATING VASCULAR DISORDERS

(57) Abstract: The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in Figure 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.



WO 2003/104282 A3

Immunoadhesin comprising a glycoprotein VI domain

The present invention relates to an immunoadhesin comprising a specific glycoprotein VI domain. The immunoadhesin of the invention is obtainable by a specific process providing the immunoadhesin in the form of a dimer. The present invention also relates to the use of the immunoadhesin of glycoprotein VI for the preparation of a medicament for the prevention of intraarterial thrombosis in a specific group of patients. Moreover, the present invention relates to the use of the immunoadhesin of glycoprotein VI for the preparation of a medicament for the prevention and treatment of atheroprogession. The present invention also relates to the use of the immunoadhesin of glycoprotein VI for the preparation of a medicament for the prevention and treatment of chronic progression of atherosclerosis in diabetic patients. The present invention also relates to *in vitro* and *in vivo* screening methods for an inhibitor of GPVI mediated adhesion of platelets to active intravascular lesions.

Acute coronary or carotid syndromes are a major cause of death in Western societies. Even in case of an initial survival of such a cardiovascular event, many patients suffer from life-threatening complications such as intravascular thrombosis leading to further myocardial infarction or stroke.

Intravascular thrombosis is the result of aggregation of platelets in a vessel whereby the blood flow in the vessel may be seriously reduced or even completely inhibited. Specifically, the disruption of an atherosclerotic plaque initiates a cascade of events culminating in arterial thrombosis and ischemia of the downstream tissue, precipitating diseases such as myocardial infarction or ischemic stroke. The first response to vascular injury is adhesion of circulating platelets to exposed subendothelial matrix proteins, which triggers subsequent platelet aggregation. Among the macromolecular components of the subendothelial layer fibrillar collagen is considered the most thrombogenic constituent, as it acts as a strong activator of platelets and supports platelet adhesion both *in vitro* and *in vivo* (1-3).

The platelet membrane proteins, which have been reported to be putative collagen receptors, may be divided into those which interact indirectly with collagen through collagen-bound von Willebrand factor (vWf), including GPIb α and the integrin $\alpha_{11b}\beta_3$, and those which interact directly with collagen including GPVI, the integrin $\alpha_2\beta_1$, and CD36 (reviewed in (2)). Only

recently, the platelet glycoprotein VI (GPVI) has been identified as the major platelet collagen receptor (4). GPVI is a 60-65 kDa type I transmembrane glycoprotein, which belongs to the immunoglobulin superfamily (5;6). In human and mouse platelets GPVI forms a complex with the FcR γ -chain at the cell surface (7;8). Ligand binding to GPVI triggers tyrosine phosphorylation of the ITAM motif of the Fc receptor γ chain initiating downstream signaling via Syk kinases, LAT, SLP-76, and phospholipase C (9-13). Platelets deficient in GPVI show loss of collagen-induced adhesion and aggregation *in vitro* (4;14). Likewise, function blocking anti-GPVI monoclonal antibodies attenuate *ex vivo* platelet aggregation in response to collagen and collagen-related peptide CRP, which mimics collagen triple helix (15;16).

It is known that the problem of complications due to the aggregation of platelets can be addressed by administering inhibitors of platelet aggregation. For the treatment of acute coronary syndromes, GP IIb/IIIa inhibitors such as ReoPro significantly improve the outcome of patients. However, a recent meta-analysis of clinical trials revealed a significant remaining risk for death or myocardial infarction despite optimal antithrombotic intervention (Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *Lancet* 2002; 359:189-98). Specific severe side effects of this therapeutic regimen are bleeding complications. These occurred in 2.4 % of the patients with the most severe form of intracranial bleeding occurring in almost 0.1 % of the treated patients. Several mechanistic shortcomings of the GP IIb/IIIa receptor blockade have been revealed which account for suboptimal effectivity and side effects (Dickfeld T, Ruf A, Pogatsa-Murray G, Muller I, Engelmann B, Taubitz W, Fischer J, Meier O, Gawaz M. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. *Thromb Res.* 2001;101:53-64. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. *Circulation.* 1999;99:E1-E11).

The inhibition of platelet aggregation leads to a general impairment of the platelets with regard to their ability to aggregate. Accordingly, not only the undesired thrombosis formation is influenced, but also the general ability of the platelets to terminate bleeding. Therefore, the administration of inhibitors of platelet aggregation inherently leads to severe side effects such as bleedings which may cause further life-threatening complications. These side effects are of

course still more problematic in patients suffering from diabetes.

Diabetes is one of the main risk factors for atherosclerosis. Additionally diabetes constitutes an increased risk of life threatening complications and excess morbidity in patients presenting with acute vascular and especially coronary syndromes. Diabetic patients with unstable angina present with a higher incidence of plaque ulceration and intracoronary thrombosis compared to non-diabetic patients. (Biondo-Zoccai GGL; Abbate A; Liuzzo G, Biasucci L: Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41; 1071-1077; 2003).

It is increasingly recognized that platelets are a major trigger for the progression of atherosclerosis. The link between increased atheroprogession, and increased platelet responsiveness and diabetes is so far an unresolved problem. Diabetic patients suffer from acute vascular complications independent of the degree of atherosclerosis indicative of different presently unknown mechanisms for platelet activation in the development of diabetic acute vascular complications and atherosclerotic acute vascular complications.

Therefore, it is the problem of the invention to provide a medicament which is useful for avoiding life-threatening complications subsequent to an acute coronary or carotid syndrome while maintaining the potency of the blood for hemostasis.

It is a further problem of the preent invention to provide a medicament for the treatment or prevention of atheroprogession.

It is a still further problem of the invention to provide a medicament for the treatment of diabetes, notably complications associated with diabetes.

It is a further problem of the invention to provide an *in vitro* and an *in vivo* screening method for inhibitors of adhesion of platelets to intravascular lesions.

GENERAL DESCRIPTION OF THE INVENTION

The above problems are solved according to the claims. The present invention provides the first direct *in vivo* evidence indicating that GPVI is in fact strictly required in the process of platelet recruitment under physiological shear stress following vascular injury. In different mouse

models of endothelial denudation both inhibition or absence of GPVI virtually abolished platelet-vessel wall interactions and platelet aggregation, identifying GPVI as the major determinant of arterial thrombus formation. This indicates that inhibition of GPVI-ligand interactions prevents arterial thrombosis in the setting of atherosclerosis. The present invention uses the antithrombotic potential of a specific soluble form of GPVI. Specifically, a fusion protein is provided, which contains the extracellular domain of GPVI and a human N-terminal Fc tag. The soluble form of human GPVI specifically binds to collagen with high affinity and attenuated platelet adhesion to immobilized collagen *in vitro* and to sites of vascular injury *in vivo*. Accordingly, the present invention is based on the recognition that the precondition for intraarterial thrombosis as an acute clinical complication is the initial adhesion of platelets to active lesions in the vessel walls. The present inventors have recognised that platelet adhesion to subendothelial matrix collagen at a lesion of the vessel wall by the glycoprotein VI (GPVI) receptor represents the key event for the formation of thrombosis. The inhibition of the adhesion of platelets to subendothelial matrix collagen of the fusion protein of the invention is therefore capable of not only preventing adhesion of platelets to an active lesion, but also to prevent aggregation of platelets at the active lesion. Thereby, the formation of intravascular thrombosis can be efficiently avoided without impairing the general ability of the platelets for aggregation.

It is surprising that the complex process of the formation of thrombosis may be inhibited by the inhibition of a single platelet receptor in view of the fact that different components of the subendothelial layers are ligands and activators of platelets such as laminin, fibronectin, von Willebrand factor (vWf) and collagen. Moreover, a wide variety of receptors on the platelets had been proposed by *in vitro* examinations, but the relevant receptor or receptor combinations which influence adhesion of platelets to lesions *in vivo* had not been known before.

The present invention is also based on the recognition that GP VI is a major mediator of platelet activity for the progression of atherosclerosis. It is demonstrated that inhibition of the collagen-mediated GPVI activation attenuates atheroprogession in atherosclerosis prone Apo e ^{-/-} mice (see figure 16). Moreover, it is demonstrated that the platelets from diabetic patients, who are also prone for advanced atherosclerosis and increased thrombotic complications show an increased expression of the GPVI-coreceptor Fc-receptor. Therefore platelets from diabetics might show increased responsiveness to collagen stimulation leading to the clinically observed

increased thrombotic complications in unstable angina, where collagen is uncovered from subendothelial vascular layers by plaque rupture or endothelial denudation.

The present invention provides therefore a treatment of atheroprogession in patients, notably in patients suffering from diabetes. Moreover, the invention provides a medicament for the treatment of acute vascular complications such as intravascular thrombosis especially in patients with diabetes. The immunoadhesin Fc-GPVI-nt is a potent therapeutic tool to attenuate atheroprogession and increased responsiveness of platelets to collagen via the GPVI receptor. Therefore, Fc-GPVI-nt is a medicament for treatment of atherosclerosis and particularly for the treatment of atherosclerotic complications in diabetes.

This invention provides a fusion protein (Fc-GPVI-nt) comprising the following segments:

- (a) the extracellular domain of glycoprotein VI (GP VI) or a variant thereof that is functional for binding to collagen and
- (b) the Fc domain of an immunoglobulin or a function-conservative part thereof.

The fusion protein is characterised by an amino acid sequence as shown in Figure 7. The fusion protein according to the invention is obtained or obtainable by

- (a) collecting 2 days after infection the culture supernatant of Hela cells infected with an adenovirus for Fc-GPVI-nt coding for an amino acid sequence as shown in figure 7;
- (b) centrifuging (3800 g, 30 min, 4°C) the supernatant of step (a);
- (c) filtrating (0.45 µm) the supernatant of step (b);
- (d) precipitating the immunoadhesin by addition of 1 vol. ammonium sulfate (761 g/l) and stirring overnight at 4°C;
- (e) pelletizing the proteins by centrifugation (3000 g, 30 min, 4°C),
- (f) dissolving the pelletized proteins of step (e) in 0.1 Vol PBS and dialysed in PBS overnight at 4°C;
- (g) clarifying the protein solution by centrifugation (3000 g, 30 min, 4°C);
- (h) loading the solution of step (g) on a protein A column (HiTrap™ protein A HP, Amersham Pharmacia Biotech AB, Uppsala, Sweden);
- (i) washing the column with binding buffer (20 mM sodium phosphate buffer pH 7.0, 0.02% NaN₃) until OD₂₈₀ < 0.01;
- (k) eluting fractions with elution buffer (100 mM glycine pH 2.7);
- (l) neutralizing the eluted fractions with neutralisation buffer (1 M Tris/HCl pH 9.0, 0.02 %

- NaN₃);
- (m) pooling the fractions;
 - (n) dialysing the pooled fractions in PBS overnight at 4°C,
 - (o) aliquoting the dialysed product and freezing at -20°C.

Under the above conditions, the fusion protein is obtained as a covalently linked dimer of a molecular mass of 160 kDa as measured under non-reducing conditions by SDS-PAGE. Dimerisation of the fusion protein presumably occurs by inter-chain disulfide bonds of cysteines in a specific domain adjacent to the GPVI fragment of the amino acid sequence as shown in Figure 7. The dimeric nature of the fusion protein depends at least from the presence of a specific region between the Fc portion and the GPVI portion as contained in Figure 7, and the preparation process. A monomeric fusion protein is not useful as a therapeutic agent in practice since the inferior binding properties of a monomeric fusion protein as compared to the dimeric fusion protein would require administration of protein in an amount which is in the order of one magnitude larger than the amount of the dimeric fusion protein for obtaining a similar effect, cf. Figure 9(e). The administration of large amounts of protein is, however, problematic from a therapeutic and economic point of view, in particular in the treatment of chronic disease.

The fusion protein of the invention is an immunoadhesin. It has a segment (a) that has the function of the extracellular domain of platelet GP VI. Said GPVI may be a mammalian GPVI, preferably it is human GPVI. Said function is preferably binding to the GP VI ligand collagen. The whole extracellular domain of GPVI may be used for said fusion protein or any fragments thereof provided said fragments are capable of binding to collagen. A variant of the fusion protein may have a modification at one or several amino acids of said fusion protein (e.g. glycosylation, phosphorylation, acetylation, disulfide bond formation, biotinylation, chromogenic labelling like fluorescein labelling etc.). Preferably, a variant is a homolog of said fusion protein. An engineered variant may be tested easily for its capability of binding to collagen using the methods disclosed herein. Most preferably, the polypeptide of residues 1 to 267 of SEQ ID No: 1 is used as segment (a). However, said polypeptide may also be modified by exchanging selected amino acids or by truncating said sequence without abolishing said function.

Segment (b) of said fusion protein serves at least one of the following purposes: secretion of the fusion protein from cells that produce said fusion protein, providing segment (a) in a form

(e.g. folding or aggregation state) functional for binding collagen, affinity purification of said fusion protein, recognition of the fusion protein by an antibody, providing favourable properties to the fusion protein when used as a medicament. Surprisingly and most importantly, segment (b) allows production of said fusion protein in mammalian, preferably human, cells and secretion to the cell supernatant in active form, i.e. in a form functional for binding to collagen. Segment (b) is most preferably an Fc domain of an immunoglobulin. Suitable immunoglobulins are IgG, IgM, IgA, IgD, and IgE. IgG and IgA are preferred. IgGs are most preferred. Said Fc domain may be a complete Fc domain or a function-conservative variant thereof. A variant of Fc is function-conservative if it retains at least one of the functions of segment (b) listed above. Most preferred is the polypeptide of residues 273 to 504 of SEQ ID No. 1. It is, however, general knowledge that such a polypeptide may be modified or truncated without abolishing its function.

Segments (a) and (b) of the fusion protein of the invention may be linked by a linker. The linker may consist of about 1 to 100, preferably 1 to 10 amino acid residues.

Most preferably, said fusion protein has the amino acid sequence of SEQ ID No. 1 (termed Fc-GPVI-nt herein).

The invention further provides a nucleic acid sequence coding for the fusion protein of the invention. Said nucleic acid sequence comprises a sequence selected from the following group:

- (i) the nucleic acid sequence of SEQ ID No: 2 or a variant thereof that codes for the same polypeptide according to the degeneracy of the genetic code;
- (ii) a nucleic acid sequence coding for a polypeptide that has at least 70 % sequence homology to the polypeptide encoded by SEQ ID No: 2;
- (iii) a nucleic acid coding for a polypeptide of at least 300 amino acids, whereby a segment of at least 100 amino acids is functional for binding to collagen and a segment of at least 200 amino acids is functional as an Fc domain; and
- (iv) a nucleic acid sequence coding for the fusion protein of claim 1.

The invention further provides a medicament for the prevention or treatment of intraarterial thrombosis, containing a protein that comprises the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen. Preferably, said protein is said fusion

protein of the invention. If said medicament contains said fusion protein, said medicament preferentially further comprises a suitable carrier. Said medicament is preferably administered parenterally, more preferably it is administered intravenously. As has been found by the present inventors, GP VI-collagen interactions are the major factor of platelet adhesion to an injured vessel wall. The fusion protein of the invention can prevent binding of platelets to blood-exposed collagen in the vascular system by blocking said blood-exposed collagen without inhibiting other platelet functions.

Alternatively, the medicament of the invention may contain a nucleic acid that codes for said fusion protein of the invention for gene therapy. Said nucleic acid preferably contains the nucleic acid sequence defined above. Said nucleic acid is preferably contained in a vector, preferentially a viral vector. Vectors encoding said fusion protein may be introduced into the vascular system of a patient such that e.g. endothelial cells are transduced therewith. Suitable vectors for gene therapy are known in the art. They may be based e.g. on adenoviruses, on adeno-associated viruses, on retro viruses, or on herpes simplex viruses. Vectors may be adopted for long-term or for short-term expression of the fusion protein by transduced cells, as the patient requires. The Fc domain of the fusion protein enables secretion of the fusion protein in active form by transduced cells.

The invention further provides a method of *in vitro* screening for inhibitors of binding of glycoprotein VI to collagen, comprising

- (i) providing a surface that exposes collagen;
- (ii) contacting a portion of said surface with the fusion protein of the invention under predetermined conditions that allow binding of said fusion protein to said surface;
- (iii) contacting another portion of said surface with said fusion protein in the presence of a test compound under conditions as in step (ii);
- (iv) determining the amount of said fusion protein bound to said surface in the absence and in the presence of said test compound;
- (v) identifying a test compound as inhibitor if binding of said fusion protein to said surface is less in the presence of said test compound as compared to the absence of the test compound; and
- (vi) optionally determining the functional effect of said inhibitor on platelet aggregation and/or platelet activation.

The surface of step (i) may be a glass or plastic surface coated with collagen. The portions of said surface may be the wells of a titer plate or a multi-well plate. A surface that exposes collagen may be easily prepared by coating a glass or plastic surface with collagen as described in the examples. Collagen-coated plates or multi-well plates are also commercially available. In step (ii), a predetermined amount of said fusion protein is contacted with a first portion of said surface under conditions (notably pH, buffer, temperature) that allow binding of the fusion protein to the surface. Preferably, conditions are chosen that allow optimal binding to said surface. In step (iii), another surface portion is contacted with the same amount of fusion protein and under the same conditions as in step (ii) in the presence of a predetermined amount or concentration of a test compound. More than one amount or concentration of a test compound may be used. Said determining of step (iv) preferably comprises washing of said surface portions contacted according to steps (ii) and (iii) one or more times in order to remove unbound fusion protein. The amount of bound fusion protein may then be determined e.g. by measuring the fluorescence of a fluorescent label (e.g. fluorescein, rhodamine etc.) attached to the fusion protein. Alternatively, bound fusion protein may be detected using an antibody against said fusion protein, whereby said antibody may be fluorescently labelled. Alternatively, the antibody may be labelled with an enzyme (e.g. alkaline phosphatase, a peroxidase, luciferase) capable of producing a coloured or luminescent reaction product. Most conveniently, the fusion protein may be labelled with a chromogenic label such that the label changes its light absorption or light emission characteristics upon binding to collagen. In this embodiment, washing off of unbound fusion protein is not needed.

In step (v), inhibitors may identified. Identified inhibitors or selected moieties thereof may be used as lead structures for improvement of the inhibitor. Such lead structures may be modified using chemical methods and the modified structures may again be tested with this screening method. Modified structures or test compounds with improved inhibition properties may be selected and optionally further varied by chemical methods. In this way, iterative improvement of an inhibitor may be achieved. The inhibitors identified using the screening methods of the invention are valuable as potential drugs against thrombosis and arteriosclerosis.

In step (vi), the functional effect of said inhibitor on platelet aggregation and/or platelet activation may be determined according to methods described below, e.g. by intravital fluorescence microscopy.

Said screening method may be carried out on small, medium, or large scale depending on the number of test compounds to be tested. If many test compounds are to be tested (e.g. libraries of chemical compounds), the screening method preferably takes the form of a high-throughput screening (HTS). For HTS, the amount of bound fusion protein is preferably detected using fluorescently labelled fusion protein.

The above screening method may also be adopted for screening for antibodies that inhibit binding of GP VI to collagen, notably antibodies against the extracellular domain of GP VI. Such an antibody screening may be combined with e.g. hybridoma technology of generating monoclonal antibodies or any other antibody generating technique, whereby the fusion protein of the invention is preferably used as antigen. Antibodies in hybridoma cell supernatants may be used as said test compounds.

The invention further provides antibodies produced by using the fusion protein of the invention as immunogen. Moreover, use of an antibody against GPVI is provided for the preparation of a medicament for the prevention of platelet adhesion at exposed subendothelial matrix collagens in active atherosclerotic lesions as the initial trigger for acute coronary or carotid syndrome. Such indications may be diagnosed as described below. Preferably, the patient is further characterized by suffering from unstable atherosclerotic plaque. Said medicament is preferably administered parenterally. Preferably, said antibodies are monoclonal antibodies. Such antibodies may e.g. be prepared using the fusion protein of the invention as immunogen.

Furthermore, the invention provides a method of *in vitro* screening for an inhibitor of GPVI mediated adhesion of platelets to active intravascular lesions, said method comprising the steps of

- (i) providing a surface exposing collagen;
- (ii) contacting the surface with platelets under predetermined conditions allowing for an adhesion of the platelets to the collagen;
- (iii) measuring the adhesion of platelets in the presence of a test compound; and
- (iv) identifying the test compound as an inhibitor of GPVI when the adhesion of platelets to collagen is less in the presence of the test compound as compared to the absence of the test compound; and
- (v) optionally determining the functional effect of said inhibitor on platelet aggregation

and/or platelet activation.

Platelets to be used in this method may be isolated according to known procedures (cf. example 7). They may be isolated from blood of mammals like mice, rats, rabbits, pigs etc. Preferably, they are isolated from humans. Said platelets may be labelled e.g. with a fluorescent dye like fluorescein. The adhesion of platelets to said surface may be measured as described in the examples. The test compounds for this method may be small organic molecules. Preferably, the test compounds for this methods are inhibitors identified in the above method of screening for inhibitors of binding of GP VI to collagen. In this way, the number of compounds to be screened using platelets can be significantly reduced and the likelihood of finding inhibitors functional with platelets can be increased.

Method of *in vivo* screening for an inhibitor of GPVI mediated adhesion of platelets to active intravascular lesions, said method comprising the steps of

- (i) providing an *in vivo* model for active intravascular lesions;
- (ii) measuring the adhesion of platelets to an active intravascular lesion in the presence of a test compound, and
- (iii) identifying the test compound as an inhibitor of GPVI when the adhesion of platelets to the active intravascular lesion is less in the presence of the test compound as compared to the absence of the test compound.

Said *in vivo* model may be a suitable mammal like a mouse, a rat, a rabbit etc. Preferably, it is a mouse. Platelets that are preferably fluorescently labelled are introduced into the model prior to measuring the adhesion of platelets to an active intravascular lesion in the presence and in the absence of a test compound. Said test compound has preferably been identified as an inhibitor in one of the above *in vitro* screening methods. Adhesion of platelets to an active intravascular lesion may be carried out by using *in vivo* fluorescence microscopy as described in example 8.

The present invention also provides a use of a fusion protein comprising

- (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and
- (b) the Fc domain of an immunoglobulin or a function-conservative part thereof,

for the manufacture of a medicament for the treatment of diabetes.

The fusion protein used for the manufacture of a medicament for the treatment of diabetes is preferably a dimeric fusion protein. In order to provide for the possibility of dimerisation, a hinge region must be present between domains (a) and (b) of the fusion protein. The hinge region is required for allowing suitable orientation of the polypeptide chains and formation of inter-chain disulfide bonds. Accordingly, the hinge region must have a sufficient length and contain cystein residues, preferably at least two cystein residues. Preferably, the fusion protein comprises residued 1 to 267 of SEQ ID No:1. The fusion protein is used for the treatment of acute complications of diabetes or for the treatment of chronic progression of atherosclerosis in diabetic patients. Preferably, the fusion protein is Fc-GPVI-nt.

The present invention also provides a method for the preparation of a fusion protein of the invention (Fc-GPVI-nt), which comprises the following steps:

- (a) collecting 2 days after infection the culture supernatant of Hela cells infected with an adenovirus for Fc-GPVI-nt coding for an amino acid sequence as shown in figure 7;
- (b) centrifuging (3800 g, 30 min, 4°C) the supernatant of step (a);
- (c) filtrating (0.45 µm) the supernatant of step (b);
- (d) precipitating the immunoadhesin by addition of 1 vol. ammonium sulfate (761 g/l) and stirring overnight at 4°C;
- (e) pelletizing the proteins by centrifugation (3000 g, 30 min, 4°C),
- (f) dissolving the pelletized proteins of step (e) in 0.1 Vol PBS and dialysed in PBS overnight at 4°C;
- (g) clarifying the protein solution by centrifugation (3000 g, 30 min, 4°C);
- (h) loading the solution of step (g) on a protein A column (HiTrap™ protein A HP, Amersham Pharmacia Biotech AB, Uppsala, Sweden);
- (i) washing the column with binding buffer (20 mM sodium phosphate buffer pH 7.0, 0.02% NaN₃) until OD₂₈₀ < 0.01;
- (k) eluting fractions with elution buffer (100 mM glycine pH 2.7);
- (l) neutralizing the eluted fractions with neutralisation buffer (1 M Tris/HCl pH 9.0, 0.02 % NaN₃);
- (m) pooling the fractions;
- (n) dialysing the pooled fractions in PBS overnight at 4°C,

76766-61

13

(o) aliquoting the dialysed product and freezing at -20°C.

Accordingly, in one aspect, the invention relates to a fusion protein comprising: a) a glycoprotein VI (GPVI) portion selected from an extracellular domain of GPVI and a variant thereof that is functional for binding to collagen; and b) an Fc portion selected from an Fc domain of an immunoglobulin and a functional conservative variant thereof, the GPVI portion and the Fc portion being fused via a linker having the amino acid sequence Gly-Gly-Arg.

In another aspect, the invention relates to the fusion protein as described above, which is a homodimeric fusion protein.

In another aspect, the invention relates to a nucleic acid molecule comprising a sequence selected from the following group: a) the nucleic acid sequence of SEQ ID NO:2 or a variant thereof that codes for the same polypeptide according to the degeneracy of the genetic code; b) a nucleic acid sequence coding for a polypeptide that has at least 70% sequence homology to the polypeptide encoded by SEQ ID NO:2, wherein the nucleic acid sequence encodes a polypeptide comprising, from its N-terminus to its C-terminus, an extracellular domain of GPVI or a variant thereof functional for binding to collagen, a linker having the amino acid sequence Gly-Gly-Arg, and an Fc domain or a functional conservative variant thereof functional for enabling a protein encoded by the nucleic acid to be secreted from a cell in a form functional for binding to collagen; and c) a nucleic acid sequence coding for a polypeptide of at least 300 amino acids and having, in the

76766-61

13a

5' to 3' direction, a first segment encoding at least 100 amino acids comprising an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen, a second segment which encodes the amino acid sequence Gly-Gly-Arg, and a third segment encoding at least 200 amino acids functional as an Fc domain for enabling a protein encoded by the nucleic acid to be secreted from a cell in a form functional for binding to collagen.

In another aspect, the invention relates to a protein encoded by the nucleic acid as described above.

In another aspect, the invention relates to a vector comprising the nucleic acid as described above.

In another aspect, the invention relates to a cell expressing the fusion protein as described above.

In another aspect, the invention relates to an anti-atherosclerotic agent for the treatment or prevention of atherosclerosis, said agent comprising two polypeptide chains encoded by the nucleic acid as described above, each having a hinge region connected to the hinge region of the other by inter-chain disulfide bonds.

In another aspect, the invention relates to a pharmaceutical composition comprising an immunoadhesin and a pharmaceutically acceptable carrier, wherein said immunoadhesin is a homodimeric fusion protein comprising an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen; and an Fc domain of an immunoglobulin or a functional conservative part thereof, the extracellular domain or variant thereof and the Fc domain or functional conservative part thereof being fused via a linker, said linker having the amino acid sequence Gly-Gly-Arg.

76766-61

13b

In another aspect, the invention relates to use of the homodimeric fusion protein as described herein for the treatment or prevention of atherosclerosis.

In another aspect, the invention relates to use of the homodimeric fusion protein as described herein for the prevention of intraarterial thrombosis in a patient.

In another aspect, the invention relates to use of the homodimeric fusion protein as described herein for the treatment or prevention of myocardial infarction and/or cerebral stroke.

In another aspect, the invention relates to a method of producing a monoclonal antibody from a non-human mammal comprising using the homodimeric fusion protein as described herein as an immunogen.

DESCRIPTION OF THE FIGURES

Figure 1 Platelet adhesion and aggregation following vascular injury of the common carotid artery in *C57BL6/J* mice *in vivo*. (a) Scanning electron micrographs of carotid arteries prior to (left panels) and 2 hrs after (right panels) vascular injury. Endothelial denudation induces platelet adhesion and aggregation, resulting in the formation of a platelet-rich (lower left) thrombus. (b) Platelet-endothelial cell interactions 5 min after vascular injury were investigated by *in vivo* fluorescence microscopy of the common carotid artery *in situ* (black columns). Animals without vascular injury served as controls (open columns). The left and right panels summarize transient and firm platelet adhesion, respectively, of eight experiments per group. Platelets were classified according to their interaction with the endothelial cell lining as described²⁴ and are given per mm² of vessel surface. Mean $\pm$ s.e.m.,

76766-61

13c

asterisk indicates significant difference compared to control, $P < 0.05$. (c) Platelet aggregation following vascular injury was determined by fluorescence microscopy *in vivo* (black columns). Animals without vascular injury served as
5 controls (open columns). Mean $\pm$ s.e.m., $n=8$ each group, asterisk indicates significant difference compared to wild type mice, $P < 0.05$. The microphotographs (right) show representative *in vivo* fluorescence microscopy images in control animals (upper panel) or following vascular injury
10 (lower panel). White arrows indicate adherent platelets.

Figure 2 Inhibition of GPVI abrogates platelet adhesion and aggregation after vascular injury. (a) Platelet adhesion following vascular injury was determined by intravital videofluorescence microscopy. Fluorescent platelets were
15 preincubated with 50 $\mu\text{g/ml}$ anti-GPVI (JAQ1) Fab fragments or control rat IgG. Platelets without mAb preincubation served as control. The left and right panels summarize transient and firm platelet adhesion, respectively. Mean $\pm$ s.e.m., $n=8$ each group, asterisk indicates significant difference compared to control,
20 $P < 0.05$. (b) Illustrates the percentage of platelets establishing irreversible adhesion after initial tethering/slow surface translocation is. (c) Platelet aggregation following vascular injury *in vivo*. Aggregation of platelets preincubated with tyrodes, irrelevant rat IgG, or anti-GPVI Fab (JAQ1) was
25 assessed by fluorescence microscopy as described. Mean $\pm$ s.e.m., $n=8$ each group, asterisk indicates significant difference compared to control, $P < 0.05$. (d) The photomicrographs show representative *in vivo* fluorescence microscopy images illustrating platelet adhesion in the absence
30 or presence of anti-GPVI Fab (JAQ1) or control IgG.

Figure 3 Platelet adhesion following endothelial denudation in GPVI-deficient mice. **(a)** JAQ1-treated mice lack GPVI. *Upper panels:* Platelets from mice pretreated with irrelevant control IgG (left) or anti-GPVI (JAQ1) (right) were incubated with FITC-labeled JAQ1 and PE-labeled anti-mouse CD41 for 10min at room temperature and directly analyzed on a FACScan™. A representative dot blot of 3 mice per group is presented. *Lower panel:* Whole platelet lysates from three control IgG or JAQ1-treated mice were separated by SDS-PAGE under non-reducing conditions and immunoblotted with FITC-labeled JAQ1, followed by incubation with HRP-labeled rabbit-anti-FITC mAb. **(b)** Scanning electron micrographs of carotid arteries 2 hrs after vascular injury in control animals (upper panels) or GPVI-depleted mice (lower panels). Endothelial denudation induced platelet adhesion and platelet aggregation in control animals. In contrast, only very few platelets attached along the damaged vessel wall in GPVI-depleted mice. Subendothelial collagen fibers are visible along the denuded area. **(c)** Platelet tethering and firm platelet adhesion, **(d)** transition from initial tethering to stable arrest (percentage of tethered platelets), and **(e)** platelet aggregation following vascular injury of the carotid artery was determined in GPVI-deficient (JAQ1-pretreated mice) or control IgG-pretreated mice (for details see Materials and Methods). The panels summarize platelet adhesion (transient and firm) and platelet aggregation in eight experiments per group. Mean $\pm$ s.e.m., asterisk indicates significant difference compared to control IgG, $P < 0.05$. **(f)** The photomicrographs show representative *in vivo* fluorescence microscopy images illustrating platelet adhesion in GPVI-deficient (JAQ1) and control IgG-treated mice.

Figure 4 Platelet adhesion to the surface of collagen coated glass coverslips under physiological flow conditions was assessed *ex vivo*. *Left panel:* Platelets from mice pretreated with irrelevant control IgG immunoadhesin (control) (left) or anti-GPVI immunoadhesin (Fc-GPVI-nt) (right) were investigated for adhesion under physiological flow conditions. The number of platelets was assessed by FACS counting of the washed coverslips at the end of each experiment. Platelet tethering as the first step of platelet adhesion was assessed after 30 seconds and firm platelet adhesion after 5 min under flow conditions. (for details see Example 6). The panels summarize transient and firm platelet adhesion in eight experiments per group. Mean $\pm$ s.e.m., asterisk indicates significant difference compared to control IgG, $P < 0.05$.

Figure 5 Interaction of Fc-GP VI-nt with collagen was monitored in an ELISA based assay.

Adhesion of the immunoadhesin Fc-GP VI-nt consisting of the extracellular domain of GP VI and the FC part of an IgG to collagen coated plates with increasing concentrations of Fc-GP VI-nt (0.5 μ g to 10 μ g) was investigated. The binding is visualised with a secondary antibody labelled with peroxidase directed to the Fc part of Fc-GP VI-nt. Peroxidase is finally detected by ELISA. In this representative experiment binding of Fc-GP VI-nt to collagen was monitored with sufficient affinity, which reached saturation at μ g concentrations.

Figure 6 Interaction of the Fc-GP VI-nt with collagen and the possibility to screen for GP VI inhibitors was demonstrated with the inhibitory anti mouse GP VI antibody JAQ 1. Adhesion of the immunoadhesin Fc-GP VI-nt (2 μ g/well) to collagen coated ELISA plates is shown to be specific: the empty immunoadhesin Fc-nt did not show any binding. Thus, this provides an ELISA based assay for the screening against GP VI inhibitors with the upscale potential to high-throughput capacities.

Figure 7 Amino acid sequence of Fc-GPVI-nt: SEQ ID No: 1.

Figure 8 DNA-Sequence of immunoadhesin Fc-GPVI-nt: SEQ ID No. 2. Bases 1 to 807 encode the extracellular domain of GP VI. Bases 817 to 1515 encode the Fc part of the IgG.

Figure 9 Characterization of GPVI-Fc. **(a) upper panel:** Fc-GPVI-nt and control Fc lacking the extracellular GPVI domain were used for SDS-PAGE under reducing conditions. Coomassie blue stain (left) and immunoblotting with peroxidase-conjugated goat anti-human Fc antibody (right) identified Fc-GPVI-nt with a molecular mass of ~80kDa. **Middle panel:** Immunoblotting of Fc, Fc-GPVI-nt, or human platelets using the anti-GPVI monoclonal antibody 5C4. 5C4 detected both adenovirally expressed Fc-GPVI-nt fusion protein and platelet GPVI, but not the control Fc. **Lower panel:** Molecular mass under reducing (right) and non-reducing (left) conditions. While the molecular mass of Fc-GPVI-nt was approximately 80 kDa under reducing conditions, the complete nt with ~160 kDa protein was identified under non-reducing conditions. **(b-d)** Characterization of Fc-GPVI-nt collagen interactions. **(b)** Binding assays using different concentrations of soluble Fc-GPVI-nt and immobilized collagen (10 μ g/ml) were performed to define Fc-GPVI-nt-collagen interactions. Bound Fc-GPVI-nt was detected by anti-Fc mAb antibody (dilution 1:10.000) and is given relative to the binding observed at 10 μ g/ml Fc-GPVI-nt. Fc-GPVI-nt binds to collagen in a saturable manner. Mean $\pm$ s.e.m., n=6 each Fc-GPVI-nt

concentration, asterisk indicates significant difference compared to 0 $\mu\text{g/ml}$ Fc-GPVI-nt, $P < 0.05$. **(c, left panel)** shows binding of Fc-GPVI-nt (20 $\mu\text{g/ml}$) to various substrates. Binding of Fc-GPVI-nt to BSA (10 $\mu\text{g/ml}$) or vWF (10 $\mu\text{g/ml}$) is given as percentage of GPVI-dimer-binding to immobilized collagen. Binding of Fc-GPVI-nt did not occur to BSA or vWF, supporting the specificity of Fc-GPVI-nt binding. Mean $\pm$ s.e.m., asterisk indicates significant difference compared to collagen, $P < 0.05$. **(c, right panel)** illustrates binding of Fc-GPVI-nt (20 $\mu\text{g/ml}$) or Fc (20 $\mu\text{g/ml}$) to immobilized collagen (10 $\mu\text{g/ml}$). Bound Fc-GPVI-nt or Fc was detected by anti-Fc mAb antibody (dilution 1:10.000) and is given relative to the binding observed with Fc-GPVI-nt. Only Fc-GPVI-nt, but not Fc or anti-Fc mAb binds to immobilized collagen. Mean $\pm$ s.e.m., $n=8$ each group, asterisk indicates significant difference compared to Fc-GPVI-nt binding, $P < 0.05$. **(d)** Fc-GPVI-nt (20 $\mu\text{g/ml}$) was preincubated for 10 min with different concentrations of soluble collagen. After incubation the plates were washed and Fc-GPVI-nt binding was detected by peroxidase-conjugated goat anti-human IgG antibody (dilution 1:10.000). Fc-GPVI-nt binding is given relative to the binding observed in the absence of soluble collagen. Soluble collagen inhibits GPVI-Fc-dimer-dimer binding to immobilized collagen in a dose-dependent manner. Mean $\pm$ s.e.m., $n=3$ each collagen concentration, asterisk indicates significant difference compared to 0 mg/ml collagen, $P < 0.05$. **(e)** The difference of the binding affinity between the monomeric form of the GPVI-Fc fusion protein and Fc-GPVI-nt was assessed in direct comparison. The binding of the monomer and dimer was assessed on collagen type 1 coated ELISA plates. Increasing concentrations of the GPVI fusion proteins bond to collagen in a stable manner. Here a Lineweaver Burke plot is demonstrated for affinity assessment (e). The affinity of the monomeric GPVI fusion protein was about 10 times lower compared to equimolar concentrations of the dimeric form Fc-GPVI-nt.

Figure 10 Fc-GPVI-nt inhibits CD 62 P activation on human platelets as a parameter of release of intracellular transmitter substances from alpha granules by increasing doses of collagen. Human platelets were isolated from whole blood and incubated with anti-CD 62 antibodies labelled with PE (for details see Material and Methods). Fluorescence was determined in a Becton Dickenson FACS device. Representative histograms are shown. Increasing concentrations of collagen from 0 to 10 $\mu\text{g/ml}$ induced a shift of fluorescence in the presence of the control Fc protein (100 $\mu\text{g/ml}$; blue line). In the presence of Fc-GPVI-nt (100 $\mu\text{g/ml}$; red line), the shift of fluorescence and hence CD 62 P activation was markedly inhibited.

Figure 11 Specific inhibition of collagen-mediated platelet aggregation and release of endogenous transmitters from dense and alpha granules by Fc-GPVI-nt. **(a)** Human platelets were incubated with control Fc (80 µg/ml) or Fc-GPVI-nt (80 µg/ml). Aggregation of platelets was induced with collagen (1 µg/ml) or ADP (5µM) or TRAP (10 µM) and aggregation was determined in an aggregometer under stirring conditions (for details see Material and Methods). Triplet measurements from n = 5 different blood donors were carried out. The means ± s.e.m are given in % aggregation of the control aggregation without fusion proteins. **(b)** ATP release was measured simultaneously in the same probes after incubation with control Fc (80 µg/ml) or Fc-GPVI-nt (80 µg/ml). The amount of ATP release is given in % of controls without fusion protein. **(c)** PDGF release was determined in human platelets with an ELISA system specific for human PDGF under basal conditions and after collagen (20µg/ml) stimulation (for details see Material and Methods). Preincubation with control Fc had no significant effect on PDGF release from collagen-stimulated platelets, whereas Fc-GPVI-nt (100 µg/ml) reduced the PDGF release significantly. Inhibition of PDGF release did not occur in unstimulated platelets.

Figure 12 Fc-GPVI-nt has no significant effect on bleeding time in human blood ex vivo. Bleeding time in human blood was measured ex vivo after ADP/collagen stimulation and epinephrine/collagen stimulation in a PFA-100 device. Fc-GPVI-nt (5 and 20 µg/ml) and Fc (5 and 20 µg/ml) did not prolong bleeding time whereas ReoPro^R in a therapeutically relevant concentration (5 µg/ml) maximally prolonged bleeding time under both conditions. The means ± s.e.m. from n = 4 blood donors with triplet measurements are summarized.

Figure 13 Fc-GPVI-nt inhibits platelet adhesion to immobilized collagen under flow conditions. Human platelets (2×10^8 cells/ml) were isolated from whole blood (for details see "materials and methods"). Plates were coated with immobilized collagen (10µg/ml) or vWF (10µg/ml). Platelet adhesion to the coated plates was determined in a parallel plate flow chamber in the presence of Fc-GPVI-nt or Fc lacking the extracellular GPVI domain (200 µg/ml). Inhibition of platelet adhesion by Fc-GPVI-nt is given in % of control (Fc control). Fc-GPVI-nt significantly attenuated platelet adhesion on immobilized collagen at shear rates of 500sec⁻¹ and 1000sec⁻¹, respectively. In contrast, Fc-GPVI-nt did not affect platelet adhesion on immobilized vWF. Mean ± s.e.m., n=4 each group, asterisk indicates significant difference compared to control Fc, $P < 0.05$. The lower panels show representative microscopic images.

Figure 14 Fc-GPVI-nt has favourable pharmacokinetics with a prolonged plasma half life after intraperitoneal injection in mice *in vivo*. Blood concentrations of Fc-GPVI-nt were determined with specific anti-Fc antibodies and ELISA (for details please see "material and methods"). **(a)** Single intraperitoneal injection of Fc-GPVI-nt (4 µg/g) led to rapid peak blood concentrations of Fc-GPVI-nt after ~ 24 h with slow decline of Fc-GPVI-nt blood concentrations. The means ± s.e.m. from 10 animals are demonstrated. **(b)** Repeated intraperitoneal applications (10 µg/g; twice weekly) leads to continuous accumulation of Fc-GPVI-nt in mice *in vivo* over 28 days. The means ± s.e.m. from 6 animals are demonstrated. **(c)** Intravenous single dose injection of 30 µg Fc-GPVI-nt (1 µg/g body weight); 60 µg (2 µg/g body weight) and 100 µg Fc-GPVI-nt (3 µg/g body weight) per mouse led to a dose-dependent increase of immunoadhesin plasma concentration. The plasma concentration in the two higher doses in these mice *in vivo* reached prolonged elevated levels from 5 to 60 minutes and after 24 hours, sufficient for effective collagen scavenging and therefore effective inhibition of GPVI receptor activation on platelets. The means ± s.e.m. from 5 animals are demonstrated.

Figure 15 Effects of Fc-GPVI-nt on platelet adhesion and aggregation *in vivo*. **(a)** Mice (n=6 per group) were treated with 2 mg/kg or 4 mg/kg Fc-GPVI-nt iv. Integrilin (0,2 mg/kg)-treated mice served as positive controls (n=8). Bleeding times were determined as described (see "materials and methods"). The Fc-GPVI-nt fusion protein did not increase tail bleeding times compared to control animals. In Integrilin-treated mice tail bleeding time was massively prolonged. ** $P < 0.05$ vs. control. **(b)** Inhibition of GPVI abrogates platelet adhesion and aggregation after vascular injury. Platelet adhesion following vascular injury was determined by intravital video fluorescence microscopy. Mice were pretreated with 1 or 2mg/kg Fc-GPVI-nt or equimolar amounts of control Fc. The left and right panels summarize platelet tethering and firm platelet adhesion, respectively. Mean ± s.e.m., n=5 each group, asterisk indicates significant difference compared to Fc, $P < 0.05$. **(c)** Effects of Fc-GPVI-nt on thrombus formation following vascular injury *in vivo*. The number of platelet thrombi (right) and the total thrombus area (left) were assessed by fluorescence microscopy as described. Mean ± s.e.m., n=5 each group, asterisk indicates significant difference compared to Fc, $P < 0.05$. **(d)** The photomicrographs show representative *in vivo* fluorescence microscopy images illustrating platelet adhesion in the absence or presence of 1 or 2 mg/kg Fc-GPVI-nt or control Fc. Bars represent 50µm. **(e)** Scanning electron micrographs of carotid arteries 1 hr

after vascular injury in Fc- or Fc-GPVI-nt treated animals. Endothelial denudation induced platelet adhesion and platelet aggregation in Fc-treated mice. In contrast, only very few platelets attached along the damaged vessel wall in Fc-GPVI-nt-treated mice. Subendothelial collagen fibers are visible along the denuded area. Bars represent 10 μ m (**f**) Fc-GPVI-nt specifically binds to the subendothelium of carotid arteries. The binding of Fc-GPVI-nt to the subendothelium was determined on carotid sections, stained with peroxidase-conjugated goat anti-human IgG antibody. Carotid arteries obtained from Fc-treated mice served as controls. Fc-GPVI-nt but not Fc control protein was detected at the subendothelium, as indicated by the brown staining. Original magnification: 100-fold.

Figure 16 Fc-GPVI-nt significantly attenuates atheroprogession in apo e $-/-$ knockout mice in vivo. Apo e $-/-$ mice were treated with Fc-GPVI-nt (4 μ g/g) or control Fc (4 μ g/g) intraperitoneally for 4 weeks twice weekly. Atheroprogession was investigated post mortem after sudan red staining of the large vessels to visualise atheroma and plaque formation. In control animals extensive plaque formation of carotid artery preparations was indicated by the red colour in particular in the branching region. In Fc-GPVI-nt treated animals atherosclerosis was almost completely abolished in carotid arteries of apo e $-/-$ mice. Representative macroscopic whole vascular preparations of the carotide arteries of an apo e $-/-$ mouse after 4 weeks treatment with Fc-GPVI-nt (left side) and of an apo e $-/-$ mouse after 4 weeks treatment with the control Fc protein (right side) are shown.

Figure 17 Freshly isolated platelets from patients suffering from diabetes mellitus show reduced expression of the fibrinogen receptor (CD61, top) and increased expression of the Fc receptor (CD32, middle) and therefore increased expression of GPVI. The correleation between CD32 expression and GPVI expression (detected by the specific monoclonal antibody 4C9) is shown on human platelets (bottom). Human platelets were isolated from whole blood from patients suffering from diabetes and incubated with fluorescent anti-CD61 and anti CD32 antibodies or FITC labelled 4C9 antibodies. Fluorescence was determined in a Becton Dickenson FACScalibur device. The means $\pm$ s.e.m. from n=111 diabetic patients and from n=363 patients without diabetes are summarized. Correlation of CD32 fluorescence and 4C9 fluorescence was calculated with the correlation coefficient $r=0.516$.

Figure 18 Amino acid sequence of a monomeric fusion protein based on Fc-GPVI-nt.

DETAILED DESCRIPTION OF THE INVENTION

A previous hypothesis suggested that platelet glycoprotein (GP) Ib binding to von vWf recruits flowing platelets to the injured vessel wall (Ruggeri, Z.M.: Mechanisms initiating platelet thrombus formation. *Thromb. Haemost.* 1997; **78**, 611-616), whereas subendothelial fibrillar collagens support firm adhesion and activation of platelets (van Zanten, G.H. *et al.* Increased platelet deposition on atherosclerotic coronary arteries. *J Clin. Invest* 1994; **93**, 615-632; Clemetson, K.J. & Clemetson, J.M. Platelet collagen receptors. *Thromb. Haemost.* 2001, **86**, 189-197). However, the present invention demonstrates by *in vivo* fluorescence microscopy of the mouse carotid artery that inhibition or absence of the major platelet collagen receptor, GPVI, instead, abolishes platelet-vessel wall interactions following an endothelial erosion. Unexpectedly, inhibition of GPVI reduces platelet tethering and adhesion to the subendothelium by approximately 89%. Furthermore, stable arrest and aggregation of platelets is virtually abolished under these conditions. The strict requirement for GPVI in these processes was confirmed in GPVI-deficient mice, where platelets also fail to adhere and aggregate on the damaged vessel wall. These findings reveal an unexpected role of GPVI in the initiation of platelet attachment at sites of vascular injury and unequivocally identify platelet-collagen interactions as the major determinant of arterial platelet-induced atherosclerotic complications.

The fact that GP VI generally functions as a receptor for the subendothelial matrix collagen has been described (Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. *J Clin Invest* 1989; **84**: 1440 – 1445). These authors characterized platelets *in vitro* originating from patients with a GP VI receptor deficiency. However, the physiological significance of the interaction of collagen and GP VI receptor in the *in vivo* context and the relative contribution of the GP VI receptor for adhesion following vascular injury was unknown. In particular, it was not known that inhibition of this receptor inhibits the key step in the formation of intravascular thrombosis that is platelet tethering. The present invention reveals the GP VI receptor as an essential receptor for platelet adhesion to the subendothelium via the attachment to subendothelial matrix collagen *in vivo*. Amongst the variety of other platelet surface proteins such as GP Ib (von Willebrand receptor), the α IIb β 3 integrin receptor, the α 2 β 1 integrin or the GP V receptors, we have surprisingly identified the GP VI receptor to be an essential receptor to mediate platelet adhesion to the vascular wall. Since platelet adhesion is the first and most important step for platelet aggregation and intraarterial thrombus formation under physiologic shear stress

conditions, the following deleterious effects leading to intraarterial occlusion are the functional basis for the clinical syndromes of myocardial infarction or cerebral stroke. In a chronic setting, the interaction of platelets with the endothelium propagates early steps of arteriosclerosis. Our invention also showed for the first time that the GP VI receptor plays a crucial role amongst the complex variety of several platelet surface proteins for initial platelet adhesion and for chronic platelet – endothelium interaction in the propagation of arteriosclerosis.

WO 01/16321 and WO 01/00810 disclose a DNA and protein sequence of the human GPVI receptor. However, the significance on platelet adhesion and activation by endothelial lesions has not been demonstrated in an *in vivo* background.

US 6,383,779 discloses fusion proteins of GPVI. However, this reference does not disclose a dimeric fusion protein or any therapeutic effect of GPVI.

Recently, the different phases of platelet-collagen interaction to artificial collagen *in vitro* during perfusion conditions were investigated (Moroi M, Jung SM, Shinmyozu K, Tzomiyama Y, Ordinas A and Diaz-Ricart M. Analysis of platelet adhesion to collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. *Blood* 1997; 88: 2081-2092). The authors of that study already pointed out the importance of collagen-GP VI interaction during shear stress conditions. However, the relevance of subendothelial matrix collagen for the adhesion could not be studied in this artificial *in vitro* situation. As a consequence of limited relevance of their *in vitro* model, the authors of the above mentioned study came to the conclusion that GP VI receptors are rather involved in platelet activation than in platelet adhesion to the endothelium. In contrast, the von Willebrand GP Ib receptor is significantly involved in platelet-subendothelial interaction. These authors also focussed all available information about platelet – collagen interaction in a review of the current literature. Previously, Moroi M and Jung, SM (Platelet receptors for collagen. *Thromb. Haemost.* 1997; 78: 439-444) have discussed collagen fibril interaction with different collagen receptors on platelets for the adhesion and thrombus formation of platelets. However, the authors did not expect a relevant role of the GP VI receptor for the adhesion in a clinically relevant *in vivo* situation as they could not validate the significance of the different collagen receptors to the adhesion process.

Therefore, the present invention provides a solution to the problem of inhibiting the relevant target for the platelet – subendothelial interaction and for platelet adhesion without provoking undesired side effects of bleeding complications. Besides the well known interaction of collagen – platelet via the GP VI receptor, we could provide data for the interaction of the native subendothelial matrix and platelets measured by *in vivo* platelet adhesion. Consecutively, we could validate the significance of the GP VI-endothelium interaction for platelet adhesion as initial step of intravascular thrombosis. Thus, our invention solves the problem of an effective antiplatelet drug treatment for the important step of platelet adhesion without undesired side effects.

Further, the invention provides an immunoadhesin (the fusion protein of the invention). In a specific embodiment, the immunoadhesin consists of the extracellular domain of the GP VI receptor together with the Fc part of an IgG immunoglobulin (Fc-GPVI-nt). This novel fusion protein is based approximately 50 % on the original DNA sequence of GP VI as published previously. The protein structure of the immunoadhesin is novel as the recombinant fusion protein does not form a membrane protein like the GP VI receptor but is a soluble, immunoglobulin-like immunoadhesin released by the respective host cell. This immunoadhesin can block the ligand-receptor interaction of collagen and GP VI. Our results demonstrate that the immunoadhesin has marked effects on the main physiological functions of platelets induced by collagen stimulation. Collagen-induced aggregation, adhesion and the release function can be inhibited by the immunoadhesin to the same extent as does a specific, monoclonal antibody. The mechanism, however, is different: whereas the antibody inhibits GP VI activation by directly binding to the ligand binding site of the GP VI receptor, the immunoadhesin scavenges the GP VI ligand collagen and therefore prevents ligand-mediated GP VI activation.

The immunoadhesin of the invention is a novel GP VI inhibitor. It has the advantage of selective inhibition of the activated branch of GP VI mediated effects by ligand scavenging. Secondary effects, like antibody mediated effects on GP VI receptor internalisation are prevented. Fc-GPVI-nt can be used for the treatment of atherosclerotic complications caused by unstable atherosclerotic plaques with plaque rupture or endothelial lesion. Therefore, the immunoadhesin Fc-GPVI-nt serves as a therapeutic inhibitor for collagen-mediated GP VI activation without affecting the intrinsic activity of the GP VI receptor with the relevant signalling system.

Moreover, the GP VI immunoadhesin serves as an ideal epitope for antibody selection. The Fc part allows the convenient purification of the protein and simple fixation to surfaces to perform large scale antibody selection against antibody libraries i.e. by phage display. The selection allows selective antibody screening to the relevant epitope that resembles the intact protein with a similar structure as the native protein.

Finally, the Fc-GPVI-nt is an important tool for the screening for inhibitors of GP VI receptor activation. We have established an ELISA-based in vitro assay simulating the collagen GP VI interaction by collagen precoated plates as the ligand. This assay can alternatively be run with fluorescence-labelled Fc-GPVI-nt and thus be upscaled to high-throughput formats. This assay allows for the screening of both, inhibitory antibodies or small molecules for their potency to inhibit GP VI function by fluorescence measurement. With this cell free screening assay, a prototype method for a high-throughput-scaleable fluorescence screening assays for drug testing has been established.

Based on the recent improvements in imaging techniques by intravascular ultrasound or nuclear magnetic resonance imaging, it is possible to identify patients with atherosclerosis being at risk of acute clinical complications such as acute coronary or carotid syndrome, whereby the patients have active lesions as possible causes for intravascular thrombosis. It is then possible by the present invention to prevent the formation of intravascular thrombosis by the administration of a medicament containing an antibody against platelet glycoprotein VI (GPVI) without undesired side effects.

Active lesions are characterized by the unmasking of subendothelial matrix collagens and platelet activation. The occurrence of such lesions can be investigated e.g. by intravascular ultrasound or thermography (e.g., Fayed and Fuster, Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circulation 2001; 89:305-316) or nuclear resonance imaging (Helft et al., Progression and Regression of Atherosclerotic Lesions. Circulation 2002; 105:993-998). Such lesions are highly probable in patients with acute coronary or carotid syndromes, and the risk of the reoccurrence of acute clinical complications such as myocardial infarction or stroke is very high, decreasing progressively with increasing time distance from the primary event.

Therefore, the present invention also provides a method of treating a patient suffering from an acute coronary or carotid syndrome, said method comprising for avoiding intravascular thrombosis the steps of

- (a) determining the presence or absence of active intravascular lesions in the patient; and
- (b) treating the patient with an antibody against platelet glycoprotein VI (GPVI) in case of the presence of intravascular lesions.

Moreover, based on the present invention, it is possible to treat patients being at risk of intravascular thrombosis due to the rupture of complex arteriosclerotic plaques. The rupture also unmasks the subendothelial collagen matrix. As a consequence of intraarterial thrombus formation, the perfusion of vital organs is blocked with the above described important and life threatening clinical syndromes.

The present invention also provides a method of treating a patient suffering from a chronic atherosclerotic syndrome, said method comprising for avoiding intravascular thrombosis the steps of

- (a) determining the presence or absence of the onset of atheroprogession in the patient; and
- (b) treating the patient with an antibody against platelet glycoprotein VI (GPVI) in case of the presence of intravascular lesions.

Accordingly, based on the present invention, it is possible to treat patients being at risk of atherosclerosis. In order to prevent atheroprogession, a patient is treated with the fusion protein of the invention in order to prevent interaction between platelets and exposed subendothelial collagen. The fusion protein of the invention blocks the ligand for the GPVI platelet receptor in the vascular wall (e.g. subendothelium) so that an interaction between the platelets and exposed collagen is inhibited.

The fusion protein of the invention may be in the form of a lyophilised powder which is dispersed in a suitable pharmaceutically acceptable liquid carrier prior to administration to a patient. The fusion protein of the invention can also be incorporated into pharmaceutical compositions suitable for parenteral, in case of the treatment of acute complications preferably intraarterial or intravenous administration. Such compositions usually comprise the fusion

protein and a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier includes solvents, dispersion media, antibacterial and antifungal agents and isotonic agents, which are compatible with pharmaceutical administration. The present invention includes methods for manufacturing pharmaceutical compositions for the treatment of chronic or acute cardiovascular disease. Such methods comprise formulating a pharmaceutically acceptable carrier with the fusion protein of the invention. In case of the treatment of acute cardiovascular disease, the composition is preferably administered intravenously or intraarterially. In case of the treatment of chronic cardiovascular disease, the composition may also be administered subcutaneously and intraperitoneally. Such compositions can further include additional active compounds, such as further polypeptides (such as insulin) or therapeutically active small molecules. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with the fusion protein of the invention and one or more additional active compounds such as insulin. In case of the coformulation of the fusion protein and insulin for the treatment of diabetic patients, it is preferred that the dosage form allows separate storage of the different proteins whereby mixing of the proteins is carried out just prior or during the administration of the composition. Accordingly, application by a multi-chamber syringe is considered. A pharmaceutical composition of the invention is formulated to be compatible with its intended parenteral route of administration. Examples of routes of parenteral administration include, e.g., intraarterial and intravenous administration. Solutions or suspensions used for parenteral may include a sterile diluent such as water for injection, saline solution, polyethylene glycols, fixed oils, glycerine, propylene glycol, TWEEN or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; chelating agents such as ethylenediaminetetraacetic acid; antioxidants such as ascorbic acid or sodium bisulfite; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride, dextrose, saccharose or mannitose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, or phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid

polyethethylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. It is especially advantageous to formulate oral or parenteral compositions in dosage unit form. A dosage unit form are discrete units suited as unitary dosages for a patient. Each unit contains a predetermined quantity of active compound to produce the desired therapeutic effect in association with the required pharmaceutical carrier. A therapeutically effective amount of fusion protein (i.e., an effective dosage) for the treatment of acute complications ranges from 0.05 to 5 mg/kg body weight, preferably 0.1 to 2 mg/kg body weight, more preferably 0.1 to 1 mg/kg body weight. A therapeutically effective amount of fusion protein (i.e., an effective dosage) for the treatment of chronic atheroprogession ranges from 0.5 to 6 mg/kg body weight, preferably 1 to 5 mg/kg body weight, more preferably 2 to 5 mg/kg body weight. The treatment of a subject with a therapeutically effective amount of the fusion protein can include a single treatment or, preferably, can include a series of treatments. In a preferred example, a subject is treated with the fusion protein of the invention against chronic atheroprogession in the range of between 0.5 to 6 mg/kg body weight, preferably 1 to 5 mg/kg body weight, more preferably 2 to 5 mg/kg body weight, at least twice per week.

Methods to investigate platelet-collagen interaction and modulation by inhibitors

Platelet aggregation and ATP release

Stimulation of mouse platelet-rich plasma with increasing concentrations of bovine type I collagen from 0.2 to 4 µg/ml elicits a dose-dependent aggregation from 2 to 95 % and a dose-dependent ATP release from 0 to 1.66 nM ATP release. A half-maximal collagen concentration was chosen for further experiments. Incubation of the mouse platelet-rich plasma with the specific anti-mouse GP VI antibody JAQ 1 (50 µg/ml and 100 µg/ml) almost completely abolished platelet aggregation after stimulation with 2 µg collagen/ml (with 50 µg JAQ 1: 2 +/- 0.7; with 100 µg JAQ 1: 1.5 +/- 0.3 %). Moreover, ATP release was inhibited in an antibody dose-dependent manner to 1.09 nM ATP (10 µg antibody/ml) or completely abolished (50 and 100 µg antibody/ml).

Similarly, incubation of mouse platelet-rich plasma with the immunoadhesin for GP VI (Fc-GPVI-nt) (50 µg/ml and 100 µg/ml) almost completely abolished platelet aggregation after stimulation with 2 µg collagen/ml (with 50 µg Fc-GPVI-nt: 2 +/- 0.7; with 100 µg Fc-GPVI-nt: 1.5 +/- 0.3 %) and ATP release to 0 nM ATP.

Therefore, the immunoadhesin sufficiently inhibited GP VI activation by scavenging the natural GP VI ligand collagen. Both the crucial platelet function aggregation and the platelet release mechanism as determined by ATP release could be influenced by the Fc-GPVI-nt.

GP VI mediated adhesion under physiological flow conditions (flow chamber)

Adhesion of platelets under physiological shear conditions was tested in a flow chamber. Initial and firm adhesion of platelets was significantly inhibited by addition of the Fc-GPVI-nt immunoadhesin by 60 % (see figure 4).

GP VI binding assay

Adhesion of Fc-GPVI-nt to collagen coated plates was determined in an ELISA based fluorescence assay. The binding of the immunoadhesin Fc-GPVI-nt dose dependently increased up to saturation levels in a concentration from 0.2 to 10 µg Fc-GPVI-nt (please see figure 5). The specificity was demonstrated by comparing binding of Fc-GPVI-nt with that of the empty immunoadhesin Fc-nt or the uncoated plastic surface (see figure 6).

Methods to investigate platelet adhesion and aggregation at vascular injury in vivo as the

crucial steps for platelet activation in acute vascular events

To test the biological significance of platelet-collagen interactions in the processes of adhesion to lesions *in vivo*, platelet-vessel wall interactions following vascular injury of the mouse carotid artery are assessed. Vascular injury to this important vascular bed may serve as a model for the first steps of arteriosclerosis such as the endothelial lesion in early stage arteriosclerosis or the plaque rupture in later stages of arteriosclerosis with the unmasking of collagen fibrils from the subendothelium. Moreover, this model allows the study of the subsequent complications of vascular injury. Small endothelial lesions lead to maximal activation of platelets with the following steps of platelet adhesion and aggregation. In further steps platelet aggregates can lead to embolism from the carotid artery with consecutive ischemic cerebral stroke. Thus, this experimental setup serves as a relevant *in vivo* model for a subgroup of patients with unstable atherosclerosis involving plaque rupture and endothelial lesions leading to acute coronary syndrome and stroke.

Vigorous ligation of the carotid artery for 5 min consistently causes complete loss of the endothelial cell layer and initiates platelet adhesion at the site of injury, as assessed by scanning electron microscopy (Fig. 1a). *In vivo* fluorescence microscopy may be used to directly visualize and quantify the dynamic process of platelet accumulation following vascular injury. Numerous platelets are tethered to the vascular wall within the first minutes after endothelial denudation (4620 ± 205 platelets/mm²). Virtually all platelets establishing contact with the subendothelium exhibit initially a slow surface translocation of the "stop-start" type (Savage, B., Saldivar, E. & Ruggeri, Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell* 1996; **84**, 289-297). While we observed transition from initial slow surface translocation to irreversible platelet adhesion in 88% of all platelets (4182 ± 253 platelets/mm²) (Fig. 1b), platelet arrest remains transient in only 12% (543 ± 32 platelets/mm²). Once firm arrest is established, adherent platelets recruit additional platelets from the circulation, resulting in aggregate formation (Fig. 1c). Similar characteristics of platelet recruitment are obtained with immobilized collagen *in vitro*. In contrast, only few platelets are tethered to the intact vascular wall under physiological conditions ($P < 0.05$ vs. vascular injury) and virtually 100% of these platelets are displaced from the vascular wall without firm arrest ($P < 0.05$ vs. vascular injury, Fig. 1a - c).

Identification of GP VI as a novel and relevant target protein in platelets for vascular injury in vivo

The high complexity of the platelet-vessel wall interaction which involves a variety of different receptors and signaling pathways makes the *in vivo* inhibition of this process very difficult. Besides GPIb-V-I-X and $\alpha_{1b}\beta_3$ integrin which interact indirectly with collagen *via* von Willebrand factor (vWF), a large number of collagen receptors have been identified on platelets, including most importantly $\alpha_2\beta_1$ integrin (Santoro, S.A. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. *Cell* 1986; **46**, 913-920), GPV (Moog, S. *et al.* Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation. *Blood* 2001; **98**, 1038-1046), and GPVI (Moroi, M., Jung, S.M., Okuma, M. & Shinmyozu, K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. *J Clin. Invest* **84**, 1440-1445). Amidst several reports on different signaling systems which play a role *in vitro*, also GPVI has now been discussed (Gibbins, J.M., Okuma, M., Farndale, R., Barnes, M. & Watson, S.P. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. *FEBS Lett.* 1997; **413**, 255-259; Nieswandt, B. *et al.* Long-term antithrombotic protection by *in vivo* depletion of platelet glycoprotein VI in mice. *J. Exp. Med.* 2001; **193**, 459-469, Nieswandt, B. *et al.* Glycoprotein VI but not $\alpha_2\beta_1$ integrin is essential for platelet interaction with collagen. *EMBO J* 2001; **20**, 2120-2130).

To directly test the *in vivo* relevance of platelet-collagen interactions in arterial thrombus formation, we inhibited or deleted GPVI *in vivo*. The monoclonal antibody (mAb) JAQ1 blocks the major collagen-binding site on mouse GPVI (Schulte, V. *et al.* Evidence for two distinct epitopes within collagen for activation of murine platelets. *J Biol. Chem.* 2001; **276**, 364-368) and almost completely inhibits firm platelet adhesion to immobilized fibrillar collagen under high shear flow conditions (Nieswandt, B. *et al.* Glycoprotein VI but not $\alpha_2\beta_1$ integrin is essential for platelet interaction with collagen. *EMBO J* 2001; **20**, 2120-2130). To study the significance of GPVI-collagen interactions in the dynamic process of platelet adhesion/aggregation in arterial thrombus formation, mice received syngeneic, fluorescence-tagged platelets pre-incubated with JAQ1 Fab fragments or isotype-matched control IgG and carotid injury was induced as described above. Very unexpectedly, we found that the inhibition of GPVI reduced initial platelet tethering following endothelial denudation in the common carotid artery by 89% ($P < 0.05$ vs. control IgG, Fig. 2a), a process thought to be mediated mainly by

GPIb α interaction with immobilized vWF (Goto, S., Ikeda, Y., Saldivar, E. & Ruggeri, Z.M. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. *J. Clin. Invest.* 1998; **101**, 479-486; Sixma, J.J., van Zanten, G.H., Banga, J.D., Nieuwenhuls, H.K. & de Groot, P.G. Platelet adhesion. *Semin. Hematol.* 1995; **32**, 89-98). Furthermore, stable platelet arrest was reduced by 93% by JAQ1 (Fig. 2a). We observed transition from initial tethering/slow surface translocation to irreversible platelet adhesion in only 58% of those platelets establishing initial contact with the subendothelial surface (compared to 89% with control IgG-pretreated platelets, $P < 0.05$, Fig. 2b). Aggregation of adherent platelets was virtually absent following pretreatment of platelets with JAQ1 Fab fragments, but not in the controls ($P < 0.05$ vs. control, Fig. 2c and d). These data demonstrated that direct platelet-collagen interactions are crucial for initial platelet tethering and subsequent stable platelet adhesion and aggregation at sites of vascular injury. Furthermore, these findings show that GPVI is a key regulator in this process, while other surface receptors, most importantly GPIb-V-IX and $\alpha_2\beta_1$, are not sufficient to initiate platelet adhesion and aggregation on the subendothelium *in vivo*.

To exclude the possibility that this effect is based on steric impairment of other receptors, e.g. GPIb-V-IX, by surface-bound JAQ1, we generated GPVI-deficient mice by injection of JAQ1 five days prior to vascular injury. As reported previously, such treatment induces virtually complete loss of GP VI e.g. by internalization and proteolytic degradation of GPVI in circulating platelets, resulting in a "GPVI knock out"-like phenotype for at least two weeks (Nieswandt, B. *et al.* Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. *J. Exp. Med.* 2001; **193**, 459-469). As illustrated in Fig. 3a, GPVI was undetectable in platelets from JAQ1-treated mice on day 5 after injection of 100 μ g/mouse JAQ1, but not control IgG, while surface expression and function of all other tested receptors, including GPIb-V-IX, $\alpha_{Ib}\beta_3$, and $\alpha_2\beta_1$ was unchanged in both groups of mice, confirming earlier results (data not shown and Nieswandt, B. *et al.* Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. *J. Exp. Med.* 2001; **193**, 459-469).

As shown by scanning electron microscopy, platelet adhesion and aggregation following endothelial denudation of the common carotid artery is virtually absent in GPVI-deficient, but not in IgG-pretreated mice (Fig. 3b). Next, *in vivo* video fluorescence microscopy was used to define platelet adhesion dynamics following vascular injury in GPVI-deficient mice (Fig. 3c - f).

The loss of GPVI significantly reduces tethering/slow surface translocation of platelets at the site of vascular injury (by 83% compared to IgG-pretreated mice, $P < 0.05$). This GPVI-independent slow surface translocation requires vWF-GPIIb/IIIa-interaction, since it is abrogated by preincubation of the platelets with Fab fragments of a function blocking mAb against GPIIb/IIIa (p0p/B) confirming the critical role of GPIIb/IIIa in this process (not shown). In the absence of GPVI, stable platelet adhesion is reduced by approximately 90% compared to the (IgG-treated) control, while aggregation of adherent platelets is virtually absent (Fig. 3b - f). We saw transition from platelet tethering to stable platelet adhesion in only 58% of all platelets initially tethered to the site of injury (compared to 89% with control mAb-pretreated platelets, $P < 0.05$, Fig. 3d), indicating that GPIIb/IIIa-dependent surface translocation is not sufficient to promote stable platelet adhesion and subsequent aggregation.

The profound inhibition of platelet tethering by GPVI blockade was surprising and suggested a previously unrecognized function of this receptor in the very initial phase of firm platelet adhesion to vascular lesions. Fibrillar collagen is a major constituent of human atherosclerotic lesions (Rekhter, M.D. Collagen synthesis in atherosclerosis: too much and not enough. *Cardiovasc. Res.* 1999; **41**, 376-384; Rekhter, M.D. *et al.* Type I collagen gene expression in human atherosclerosis. Localization to specific plaque regions. *Am. J Pathol.* 1993; **143**, 1634-1648); enhanced collagen synthesis (by intimal smooth muscle cells and fibroblasts) significantly contributes to luminal narrowing in the process of atherogenesis (Opsahl, W.P., DeLuca, D.J. & Ehrhart, L.A. Accelerated rates of collagen synthesis in atherosclerotic arteries quantified *in vivo*. *Arteriosclerosis* 1987; **7**, 470-476). Plaque rupture or fissuring (either spontaneously or following balloon angioplasty) results in exposure of collagen fibrils to the flowing blood.

The invention teaches for the first time that such subendothelial collagens are the major trigger of arterial thrombus formation and reveal an unexpected function of the collagen receptor GPVI in platelet recruitment to the injured vessel wall. The processes of platelet tethering and slow surface translocation under conditions of elevated shear are known to largely depend on GPIIb/IIIa interaction with immobilized vWF. This interaction is, however, not sufficient to establish initial platelet-vessel wall interactions *in vivo* as functional GPVI is also required (Fig. 2 and 3). Thus, both GPIIb/IIIa and GPVI must act in concert to recruit platelets to the subendothelium. During

platelet tethering, ligation of GPVI can shift $\alpha_{IIb}\beta_3$ and $\alpha_2\beta_1$ integrins from a low to a high affinity state. Both $\alpha_{IIb}\beta_3$ and $\alpha_2\beta_1$ then act in concert to promote subsequent stable arrest of platelets on collagen, while $\alpha_{IIb}\beta_3$ is essential for subsequent aggregation of adherent platelets. Thus, ligation of GPVI during the initial contact between platelets and subendothelial collagen provides an activation signal that is essential for subsequent stable platelet adhesion and aggregation. Importantly, occupation or lateral clustering of GPIb α (during GPIb α -dependent surface translocation), which induced low levels of $\alpha_{IIb}\beta_3$ integrin activation *in vitro* (Kasirer-Friede, A. *et al.* Lateral clustering of platelet GP Ib-IX complexes leads to up-regulation of the adhesive function of Integrin $\alpha_{IIb}\beta_3$. *J. Biol. Chem.* 2002; Vol 277: 11949-11956), is not sufficient to promote platelet adhesion *in vivo*.

The invention therefore has identified an essential receptor for inhibiting platelet attachment to the subendothelium. An antibody which blocks the interaction of GPVI with exposed collagen can specifically inhibit all major phases of thrombus formation, i.e. platelet tethering, firm adhesion, and aggregation at sites of arterial injury (e.g. during acute coronary syndromes). The very profound protection that was achieved by inhibition or depletion of GPVI establishes the importance of selective pharmacological modulation of GPVI-collagen interactions to control the onset and progression of pathological atherosclerotic lesions.

Following rupture of the atherosclerotic plaque, exposure of subendothelial collagen is the major trigger that initiates platelet adhesion and aggregation at the site of injury, followed by arterial thrombosis (1;24;25). The platelet glycoprotein GPVI, which has been cloned recently (5;6), has been identified by the invention to be the major platelet collagen receptor (4), mediating platelet adhesion both *in vitro* (22) and under (patho-)physiological conditions *in vivo* (3). Therefore, inhibition of GPVI prevents platelet recruitment and arterial thrombosis in patients with advanced atherosclerosis as shown by the present invention by the inhibitory activities of the specific fusion protein Fc-GPVI-nt on platelet adhesion *in vitro* and *in vivo*.

The Fc-GPVI-nt fusion protein is expressed in HELA cells using an adenoviral expression system to obtain soluble Fc-GPVI-nt. Characterization of the soluble forms of GPVI revealed that Fc-GPVI-nt is secreted as dimer with a molecular mass of approximately 160 kDa. Consistently, Miura and co-workers recently reported that GPVI-Fc-dimer is present as a dimer,

in which two GPVI-Fc-dimer molecules are cross-linked by disulfide bonds formed from the Cys in the Fc domain of each molecule (21). Importantly, only the dimeric form of GPVI, but not monomers of the extracellular domain of GPVI, has been reported to exhibit collagen binding affinity and to attenuate collagen-induced platelet aggregation (21).

Binding assays were performed to define GPVI-Fc-dimer-collagen interaction. Soluble GPVI binds to immobilized collagen in a saturable manner. GPVI-Fc-dimer binding to fibrillar collagen was highly specific, since it did not occur to immobilized vWF or BSA. Further, GPVI binding to immobilized collagen could be inhibited by soluble collagen. High concentrations of soluble collagen were required to block GPVI-Fc-dimer binding, indicating the fusion protein binds immobilized collagen with high affinity. Correspondingly, a high association and dissociation constant (K_D approximately 5.8×10^{-7} M) has been reported for the GPVI-collagen interaction (21).

Soluble Fc-GPVI-nt has been demonstrated earlier to attenuate platelet activation and aggregation in response to collagen or convulxin, a snake toxin, which binds to GPVI with high affinity (6;21;27). Apart from platelet aggregation, GPVI is critically involved in the process of platelet adhesion to collagen (3;22). In the present study, we, therefore, tested the effects of Fc-GPVI-nt on platelet adhesion under physiological flow conditions *in vitro*. We show that soluble Fc-GPVI-nt dose-dependently inhibits platelet adhesion under low and high shear conditions *in vitro*. In the presence of Fc-GPVI-nt, but not of control Fc peptide, aggregation of adherent platelets was virtually absent, indicating that GPVI contributes to the processes of both platelet adhesion and subsequent activation by immobilized collagen. GPVI confers collagen responses (i.e. adhesion and aggregation) in a receptor density-dependent fashion (22). Correspondingly, it has been reported that a more than 50% reduction in GPVI expression transfected RBL-2H3 cells is associated with a lack of collagen-induced aggregation in these cells (8;22). Since a low variability in the GPVI receptor density has been reported albeit in a small sample population (22), one might expect that inhibition of approx. 50% of collagen-GPVI bonds is sufficient to attenuate platelet recruitment to exposed collagen. In the present study doses of 1mg/kg Fc-GPVI-nt were required to induce significant inhibition of platelet adhesion under flow, supporting the notion that multiple GPVI binding sites are available in each collagen fibril. Similar amounts of a function blocking anti-GPVI antibody were required to attenuate platelet-vessel wall injury *in vivo* (3).

Fibrillar collagen is a major constituent of the normal vessel wall but also of atherosclerotic lesions (28). Rupture or fissuring of the atherosclerotic plaque results in exposure of collagen fibrils to circulating platelets. As reported earlier, GPVI-collagen interactions are essentially involved in arterial thrombus formation following vascular injury (3). Here we demonstrate the *in vivo* effects of soluble Fc-GPVI-nt on platelet recruitment after arterial injury. Endothelial denudation was induced by reversible ligation of that carotid artery and the dynamic process of platelet attachment was monitored by intravital videofluorescence microscopy as described (3). We demonstrate for the first time *in vivo* that soluble Fc-GPVI-nt attenuates stable platelet tethering, adhesion and platelet aggregation following endothelial denudation. Inhibition of platelet recruitment by Fc-GPVI-nt was dose-dependent. Apart from preventing stable arrest of platelets, Fc-GPVI-nt significantly reduced initial platelet tethering/slow surface translocation at sites of endothelial denudation. We have demonstrated earlier that inhibition of GPIba or of GPVI attenuate platelet tethering to a similar extent (3), supporting that GPVI and GPIb α interaction need to act in contact to promote platelet tethering to subendothelial collagen (2;29-31). In fact, the high "on"- and "off"-rates reported for the GPVI-ligand interaction (22) are consistent with the role of GPVI as a tethering receptor.

The present invention identifies Fc-GPVI-nt as an active ingredient of a medicament to attenuate arterial thrombosis following vascular injury. This concept is further supported by the observation that Fc-GPVI-nt is targeted to the exposed subendothelium at the site of vascular injury, as demonstrated by immunohistochemistry. This implicates that inhibition of GPVI-collagen interactions are likely to be restricted to the site of vascular injury, while a prolonged systemic inhibition of platelet function is limited by the expected short half-life of unbound Fc-GPVI-nt. In contrast, administration of monoclonal antibodies directed against GPVI inevitably leads to systemic inhibition of GPVI on all circulating platelets. In addition, Fc-GPVI-nt administration did not affect platelet counts. In contrast, anti-GPVI mAbs may eventually induce immune thrombocytopenia or a complete loss of GPVI on circulating platelets (14;32), hampering their use in clinical practice. Accordingly, Fc-GPVI-nt therapy will likely be associated with a lower risk of clinical hemorrhage, compared to anti-GPVI mAb-based strategies.

Platelet adhesion and aggregation at sites of vascular injury is crucial for hemostasis but may lead to arterial occlusion in the setting of atherosclerosis and precipitate diseases such as

coronary thrombosis and myocardial infarction. The use of intravenous GPIIb-IIIa receptor inhibitors, has significantly improved the clinical success of patients undergoing coronary stenting (33-35). However, severe bleeding complications have been reported to hamper the outcome of patients treated with abciximab (36). The present invention demonstrates that inhibition of GPVI-collagen interactions by Fc-GPVI-nt was sufficient to significantly reduce platelet adhesion both *in vitro* and *in vivo*; however, the soluble form of GPVI only moderately prolonged tail bleeding times. Similarly, mild bleeding disorders have been reported in patients with GPVI-deficient platelets (37), indicating that coagulation and hemostasis are effective even in the complete absence of GPVI. In part this discrepancy may be due to the fact that inhibition or absence of GPVI does not interfere with platelet aggregation in response to platelet agonists other than collagen, e.g. ADP, tissue factor or thrombin. In contrast, direct inhibition of GPIIb-IIIa, e.g. by 7E3 or its humanized derivative, blocks fibrinogen binding to platelets, a process which is essential for platelet aggregation, and substantially attenuates platelet aggregation to most platelet agonist known thus far. Accordingly, Fc-GPVI-nt therapy are associated with a lower risk of clinical hemorrhage, compared to anti-GPIIb-IIIa-based strategies.

In conclusion, the present invention provides the first *in vivo* evidence that Fc-GPVI-nt attenuates platelet adhesion under flow *in vitro* and following endothelial denudation in the carotid artery of mice *in vivo*. This further supports the concept that GPVI-collagen interactions play a central role in all major phases of thrombus formation, i.e. platelet tethering, firm adhesion, and aggregation at sites of arterial injury (e.g. during acute coronary syndromes). The present invention further supports the concept that GPVI plays a major role in the progression of atherosclerosis. Moreover, the present invention shows for the first time the causal connection between GPVI and diabetes.

The invention will now be described in further detail with reference to the following specific examples.

EXAMPLES

Animals. Specific pathogen-free C57BL6/J mice were obtained from Charles River (Sulzfeld, Germany). For experiments, 12-weeks-old male mice were used. All experimental procedures performed on animals were approved by the German legislation on protection of animals.

Monoclonal antibodies. Monoclonal antibody (mAb) anti GPVI (JAQ1) and anti GPIb α (p0p/B) and Fab fragments from JAQ and p0p/B were generated as described (Bergmeier,W., Rackebrandt, K., Schroder,W., Zirngibl,H. & Nieswandt,B. Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. *Blood* 2000; **95**, 886-893; Nieswandt,B., Bergmeier,W., Rackebrandt,K., Gessner,J.E. & Zirngibl,H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. *Blood* 2000; **96**, 2520-2527). Irrelevant control rat IgG was obtained from Pharmingen (Hamburg, Germany).

Generation of GPVI-deficient mice.

To generate mice lacking GPVI, C57BL6/J wild-type mice were injected with 100 μ g JAQ1 i.c. Animals were used for *in vivo* assessment of platelet adhesion on day 5 after mAb injection. Absence of GPVI expression on platelets was verified by Western blot analysis and flow cytometry.

Flow cytometry

Heparinized whole blood, obtained from wild type C57BL6/J mice or GPVI-depleted mice was diluted 1:30 with modified Tyrodes-HEPES buffer (134 mM NaCl, 0.34 mM Na₂HPO₄, 2.9mM KCl, 12mM NaHCO₃, 20mM HEPES, 5mM glucose, and 1mM MgCl₂, pH 6.6). The samples were incubated with fluorophore-labeled mAb anti-GPVI (JAQ1) and anti-CD41 for 10 min at room temperature and directly analyzed on a FACScanTM (Becton Dickinson).

Cloning, viral expression and purification of soluble human and murine GPVI. To generate a soluble form of human GPVI, the extracellular domain of human GPVI was cloned and fused to the human immunoglobulin Fc domain according to the following examples 1 to 3. Adenoviral constructs coding for the GPVI-Fc-fusion protein or control Fc were prepared to generate the recombinant protein. GPVI-Fc and control Fc were expressed as secreted soluble proteins using the human HELA cell line to prevent misfolding and non-glycosylation of the expressed proteins.

Example 1: Cloning of the immunoadhesin of GP VI (Fc-GPVI-nt)

We generated an immunoadhesin of the GP VI receptor by generating a recombinant fusion

protein of the n-terminal part of GP VI –which encodes the extracellular domain of GPVI– together with the Fc part of an IgG. The Fc was amplified from a human heart cDNA library (Clontech, Palo Alto, CA) by PCR using the forward primer 5'-cgcggggcgccgcgagtc-ccaaatctgtgacaaaac-3' and the reverse primer 5'-gcggggaagctttcatttaccgagacagggag-3'. The PCR reaction was performed at 58°C annealing temperature and 20 cycles with the Expand High Fidelity PCR Sytem (Roche Molecular Biochemicals, Mannheim, Germany). The PCR fragment was cloned in the plasmid pADTrack CMV with NotI/HindIII and the sequence was checked by sequencing (MediGenomix, Martinsried, Germany).

For cloning of the extracellular domain of the human GPVI RNA from cultured megakaryocytes was isolated (RNeasy Mini Kit; Qiagen, Hilden, Germany) according to the manufacturers protocol and reverse transcription was performed (Omniscript RT Kit; Qiagen) with 2µg RNA at 37°C overnight. 100 ng of the reaction was used as a template in PCR amplification of the hGPVI with the primer 5'-gcggggagatctaccacatgtctccatccccgacc-3' and 5'-cgcggggcgccgcgcttgcccttggtgtagtag-3'. The PCR reaction was performed at 54°C annealing temperature and 24 cycles with the Expand High Fidelity PCR Sytem (Roche Molecular Biochemicals, Mannheim, Germany). The PCR fragment was cloned in the plasmid pDATrack CMV Fc with BglII/NotI and the sequence was checked by sequencing.

Construction of a monomeric fusion protein based on Fc-GPVI-nt

The Fc monomer fragment was amplified by PCR using the primer pair 5'-cgcggggcgccgcgcccagcacctgaactcctg-3' and 5'-cgcggggatatctcatttaccgagacagggag-3' and pADTrack CMV gpVI-Fc as a template. The PCR reaction was performed at 58°C annealing temperature and 20 cycles with the Expand High Fidelity PCR Sytem (Roche Molecular Biochemicals, Mannheim, Germany). The Fc monomer PCR fragment (NotI/EcoRV) and the gpVI fragment from pADTrack CMV gpVI-Fc (BglII/NotI) were cloned as described above.

Example 2: Generation of the adenovirus for Fc-GPVI-nt (Ad-Fc-GPVI-nt)

The plasmid pADTrack CMV Fc-GPVI-nt was linearized with PmeI (New England Biolabs, Beverly, MA) overnight, dephosphorylated and purified (GFX DNA and Gel Purification Kit; Amersham Pharmacia Biotech, Uppsala, Sweden). For recombination electrocompetent *E.coli* BJ5183 (Stratagene, La Jolla, California) were cotransformed with 1 µg of the linearized plasmid and 0.1 µg pAdeasy1 at 2500 V, 200 Ω and 25 µFD (*E.coli*-pulser; Biorad, Heidelberg,

Germany), plated and incubated overnight at 37°C. The colonies were checked after minipreparation of the plasmid-DNA with PacI and the positive clones were retransformed in *E.coli* DH5 α .

For transfection (Effectene Transfection reagent; Qiagen, Hilden, Germany) of 293 cells plasmid-DNA was digested with PacI. The cells were cultured for 7 days and harvested by scraping and centrifugation. The pellet was resuspended in Dulbecco's PBS and the cells were lysed by four repetitive freezing (-80°C) and thawing (37°C) cycles. Cell debris was removed by centrifugation and the lysate stored at -80°C.

For plaque selection of recombinant virus 293 cells are infected in Dulbeccos PBS for 1 hour at room temperature under gentle agitation with different serial dilutions of lysate from transfection. Following the infection, the cells are overlaid with growth medium containing 0.5% agarose (1:1 mix of modified Eagles medium 2x, Gibco Life Technologies #21935, supplemented with 20% serum, 2x Pencillin/Streptomycin, 2x L-glutamin and agarose in water 1%, Seacam). 5-14 days post infection the cell layer was monitored for formation of plaques which were picked using a pasteur pipett, resuspended in 0,5ml Dulbeccos PBS and stored at -80°C. The plaques were used for further amplification rounds on 293 cells.

Construction of human gpVI-Fc monomer expressing stable CHO

The monomer expressing cells were generated in accordance with example 2.

Example 3: Fc-GPVI-nt protein and Fc control immunoadhesin purification

The culture supernatant of Ad-Fc-GPVI-nt-infected Hela cells was collected 2 days after infection, centrifugated (3800 g, 30 min, 4°C) and filtrated (0.45 μ m). The immunoadhesin was precipitated by addition of 1 vol. ammonium sulfate (761 g/l) and stirred overnight at 4°C. The proteins were pelleted by centrifugation (3000 g, 30 min, 4°C), dissolved in 0.1 Vol PBS and dialysed in PBS overnight at 4°C. The protein solution was clarified by centrifugation (3000 g, 30 min, 4°C) and loaded on a protein A column (HiTrapTM protein A HP, Amersham Pharmacia Biotech AB, Uppsala, Sweden). The column was washed with binding buffer (20 mM sodium phosphate buffer pH 7.0, 0.02% NaN₃) until OD₂₈₀ < 0.01 and eluted with elution buffer (100 mM glycine pH 2.7). The eluted fractions were neutralized with neutralisation buffer (1 M Tris/HCl pH 9.0, 0.02 % NaN₃), pooled, dialysed in PBS overnight at 4°C, aliquotated and frozen at

-20°C.

The molecular mass of Fc-GPVI-nt protein was ~80kDa under reducing conditions in SDS-PAGE, as detected by Coomassie blue stain or by immunoblotting with peroxidase-conjugated goat anti-human Fc antibody or by the anti-GPVI mAb 5C4 (Fig. 1a, upper and middle panel). In contrast, a ~160 kDa protein was identified under non-reducing conditions (Fig. 1a, lower panel), supporting the notion that GPVI-Fc is obtained solely as dimer (21).

Example 4: *GP VI inhibitor screening assay*

ELISA plates (Immulon2 HB, Dynx Technologies, Chantilly, VA) were coated overnight at 4°C with 1 µg/well collagen (type I bovine; BD Bioscience, Bedford, MA) in 100 µl 50 mM Tris/HCl pH 8.0. The plate was washed with 250 µl/well PBS/0.05 % Tween 20 (PBST) twice and blocked with 250 µl/well Roti-Block (Roth, Karlsruhe, Germany) overnight. The plate was washed with 250 µl/well PBST twice, 100 µl Fc-GPVI-nt in PBST was added (optimal 2µg/well) and the plate was incubated for 1 h at room temperature. After 5-fold washing with 250 µl PBST 100 µl peroxidase-conjugated goat anti-humanIgG antibody (Dianova, Hamburg, Germany) was added in a dilution of 1:10000 and incubated for 1 h at room temperature. After repeated washing with 250 µl PBST 100 µl detection reagent (BM Blue POD Substrate; Roche, Mannheim, Germany) was added and incubated for 15 min. The reaction was stopped by the addition of 100 µl 1 M H₂SO₄ and the plate was measured at 450 nm against the reference wavelength 690 nm. To screen for potential inhibitors, test compounds are added to the incubation in 100 µl PBST at various concentrations.

Example 5: *Platelet aggregation and luminometry*

Platelet aggregation ex vivo and in vitro was evaluated by optical aggregometry in citrated blood samples at 37° C using a two channel Chronolog aggregometer (Nobis, Germany). Platelet-rich plasma was prepared from citrated whole blood by centrifugation (200 g for 20 min). The final platelet count was adjusted to 2 x 10⁸ platelets/ml with autologous plasma. After adjustment of the baseline, collagen (type I, bovine) from 0.2 to 4 µg/ml was added and aggregation was recorded for 5 min. Simultaneously, release of ATP was recorded using the firefly luminometer method. Incubation with the monoclonal GP VI antibody JAQ 1 was performed for 15 min with 50 µg/ml antibody.

Example 6: In vitro platelet adhesion assay for GP VI / collagen interaction

From ACD (20% final concentration) blood platelet rich plasma was prepared and adjusted to a final concentration of 10^8 platelets/ml by Hepes Tyrode (pH 6.5). Coverslips were coated with monolayers of various adhesive proteins (Collagen, vWF) at different concentrations. Perfusion studies were carried out in a perfusion chamber generated from glass coverslips. Perfusion was performed at shear rates of 500/s representing low-medium flow and 2000/s representing high shear rates. Adhesion was measured at 37°C for 20 minutes and then drawn through the chamber at fixed wall shear rates for 5 minutes using an automated syringe pump. After perfusion the coverslips were gently washed with Hepes Tyrode, taken from the chamber. Coverslips were repeatedly washed with Hepes Tyrode to completely remove adhesive platelets. The platelets in suspension were quantitatively analysed by FACS measurements. The analysis of the functional status of platelets was further assessed by analysis of surface marker expression (CD 41; CD 61 and CD 62 P) according to the standard flow cytometry protocol.

Example 7: Preparation of platelets for intravital microscopy

Platelets (wild type, or GPVI-deficient) were isolated from whole blood as described (Massberg, S. *et al.* Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. *Blood* 1998; **92**, 507-515) and labeled with 5-carboxyfluorescein diacetate succinimidyl ester (DCF). The DCF-labeled platelet suspension was adjusted to a final concentration of 200×10^6 platelets /250 μ l. Where indicated, fluorescent wild type platelets were preincubated with 50 μ g/ml anti-GPVI (JAQ1) Fab fragments, or anti GPIIb α (p0p/B) Fab fragments for 10 min. Subsequently, the pretreated platelets together with the Fab fragments were infused into wild type recipient mice and platelet adhesion was assessed prior to and after carotid injury by *in vivo* video microscopy, as described below.

Example 8: Assessment of platelet adhesion and aggregation by intravital microscopy.

Wild type C57BL6/J or GPVI-deficient mice were anesthetized by intraperitoneal injection of a solution of midazolam (5 mg/kg body weight, Ratiopharm, Ulm, Germany), medetomidine (0.5 mg/kg body weight, Pfizer, Karlsruhe, Germany), and fentanyl (0.05 mg/kg body weight, CuraMed Pharma GmbH, Munich, Germany). Polyethylene catheters (Portex, Hythe, England) were implanted into the right jugular vein and fluorescent platelets (200×10^6 /250 μ l) were infused intravenously. The right common carotid artery was dissected free and ligated

vigorously near the carotid bifurcation for 5 min to induce vascular injury. Prior to and following vascular injury, the fluorescent platelets were visualized *in situ* by *in vivo* video microscopy of the right common carotid artery. Platelet-vessel wall interactions were monitored using a Zeiss Axiotech microscope (20 x water immersion objective, W 20x/0.5, Zeiss) with a 100W HBO mercury lamp for epi-illumination. All video-taped images were evaluated using a computer-assisted image analysis program (Cap Image 7.4, Dr. Zeintl, Heidelberg, Germany). Transiently adherent platelets were defined as cells crossing an imaginary perpendicular through the vessel at a velocity significantly lower than the centerline velocity; their numbers are given as cells per mm² endothelial surface. The number of adherent platelets was assessed by counting the cells that did not move or detach from the endothelial surface within 10 seconds. The number of platelet aggregates at the site of vascular injury was also quantified and is presented per mm².

Example 9: Scanning electron microscopy.

Following intravital videofluorescence microscopy, the carotid artery was perfused with PBS (37°C) for 1 min, followed by perfusion fixation with phosphate-buffered glutaraldehyde (1% vol/vol). The carotid artery was excised, opened longitudinally, further fixed by immersion in 1% PBS-buffered glutaraldehyde for 12 hours, dehydrated in ethanol, and processed by critical point drying with CO₂. Subsequently, the carotid artery specimens were oriented with the lumen exposed, mounted with carbon paint, sputter coated with platinum, and examined using a field emission scanning electron microscope (JSM-6300F, Jeol Ltd., Tokyo, Japan).

Example 10: Assessment of Fc-GPVI-nt binding to immobilized collagen. The binding of Fc-GPVI-nt to immobilized collagen was determined. ELISA plates (Immulon2 HB, Dynx Technologies, Chantilly, VA) were coated over night at 4°C with 1 µg collagen (type I bovine; BD Bioscience, Bedford, MA) in 100 µl coating buffer (1.59 g/l Na₂CO₃, 2.93 g/l NaHCO₃, 0.2 g/l NaN₃, pH 9.6). The plates were washed with 250 µl/well PBS/0.05 % Tween 20 (PBST) twice and blocked with 250 µl/well Roti-Block (Roth, Karlsruhe, Germany) over night. The plates were washed with 250 µl/well PBST twice, then 3.0, 6.0, 12.5, 25.0, 50.0 or 100 µg/ml Fc-GPVI-nt in PBST was added and the plate was incubated for 1 hr at room temperature. Where indicated, Fc-GPVI-nt (20 µg/ml) was preincubated for 10 min with soluble collagen. After incubation the plates were washed 5 times with 250 µl PBST and peroxidase-conjugated goat anti-human IgG antibody Fcγ fragment specific (109-035-098; Dianova, Hamburg, Germany) was added in a

76766-61

42

dilution of 1:10.000 and incubated for 1 hr at room temperature. After 5 fold washing with 250 μ l PBST 100 μ l detection reagent (BM Blue POD Substrate; Roche, Mannheim, Germany) was added and incubated up to 10 min. The reaction was stopped by the addition of 100 μ l 1 M H_2SO_4 and the plate was measured at 450 nm against reference wavelength 690 nm.

Fc-GPVI-nt showed a dose-dependent and saturable binding to immobilized collagen (Fig. 9b). Half maximal collagen binding was observed at a final Fc-GPVI-nt concentration of 6.0 μ g/ml. Binding of GPVI-Fc did not occur to BSA, vWF (Fig. 9c, left panel) or Poly-L-Lysin (*not shown*), supporting the specificity of Fc-GPVI-nt binding. Moreover, we did not detect any significant binding of the control Fc protein lacking the external GPVI domain under identical conditions (Fig. 9c, right panel).

To further address the specificity of GPVI-binding, we the ability of solubilized fibrillar collagen to compete with immobilized collagen for the association with Fc-GPVI-nt was tested. Soluble collagen inhibited Fc-GPVI-nt-binding to immobilized collagen in a dose-dependent manner (Fig. 9d). A concentration of 100 μ g/ml soluble collagen was required to reduce Fc-GPVI-nt binding by more than 50%. Together, these data indicated that Fc-GPVI-nt binding to collagen is specific and characterized by high affinity.

Example 11: Generation of monoclonal antibody against human GPVI. Monoclonal antibodies were generated essentially as described (17). Lou/C rats were immunized with the adenovirally expressed human Fc-GPVI-nt fusion protein. Screening of hybridoma supernatants was performed in a solid-phase immunoassay using Fc-GPVI-nt or FC lacking the GPVI domain. Screening identified the supernatant of hybridoma 5C4 to bind specifically to Fc-GPVI-nt but not to Fc lacking the external GPVI domain. The immunoglobulin type was determined with rat Ig class (anti-IgM) and IgG subclass-specific mouse mAbs. The monoclonal antibodies were purified using Protein G-Sepharose^{*} columns. Antibody specificity of 5C4 was verified by immunoblotting against Fc-GPVI-nt and control Fc. 5C4 monoclonal antibody detected adenovirally expressed Fc-GPVI-nt but not control Fc. Furthermore, human GPVI was recovered in lysates obtained from human platelets. In addition, 5C4 binds specifically to the surface of platelets but not of leukocytes or red blood cells, as demonstrated using flow cytometry (*not shown*).

*Trade-mark

Example 12: FACS measurement of CD62 P externalisation. Human citrate blood was collected from volunteers. Platelet rich plasma (PRP) was generated after centrifugation and washing procedures (PBS 1 x; pH 7.2) with 2000 rpm at 4°C and resuspension. PRP diluted in staining buffer (1x PBS (w/o Ca^{2+} and Mg^{+}) with 0,1% sodium azide and 2% fetal bovine serum (FBS), 2mM CaCl) was incubated with equine collagen type 1 (0; 2; 5 and 10 µg/ml; Nobis) in the presence of Fc-GPVI-nt (100µg/ml) or equimolar concentrations control Fc. Anti CD 62P antibodies labelled with the fluorophor peroxidase (Immunotech) were added. FACS measurement was performed with an Becton Dickenson FACScalibur device.

Increasing concentrations of collagen led to platelet secretion from alpha granules indicated by CD 62P externalisation. Co-incubation of collagen with Fc-GPVI-nt blunted the CD62 P externalisation determined by FACS (Fig 10).

Example 13: Platelet aggregation and ATP release. PRP was generated as described above. Aggregation was determined in a Whole-Blood-Aggregometer 500VS (Chrono-Log Corporation). Platelet cell number from PRP was adjusted to $1,0 \times 10^8$ cells/ml by Thyrodes-HEPES buffer (2.5 mmol/l HEPES, 150 mmol/l NaCl, 12 mmol/l NaHCO_3 , 2,5 mmol/l KCl, 1 mmol/l MgCl_2 , 2 mmol/l CaCl_2 , 5,5 mmol D-Glucose, 1 mg/ml BSA, pH 7.4). Chrono-Lume #395 (Chrono-Log Corporation) was added for ATP measurement. Agonists were added to the platelets, pipetted into the aggregometer and aggregation was started under defined stirring conditions. Aggregation was determined by change of light transmission due to coagulating platelets and normalised to an internal standard. ATP release is determined at the characteristic wavelength of Chrono-Lume for ATP and normalised to an internal standard according to the manufacturer's instructions.

Platelet aggregation and ATP release was specifically inhibited by Fc-GPVI-nt for collagen mediated agonist stimulation (Fig 11 a & b). ADP- and thrombin-mediated (TRAP 10 µM) platelet aggregation and ATP release was unaffected by Fc-GPVI-nt.

Example 14: PDGF release from human platelets. PRP from human volunteers was prepared as described above. PDGF release from human platelets was determined with a kit system (R & D Systems # DHD00B) according to the manufacturer's instructions. PDGF release was stimulated with collagen type 1 (20 µg/ml; Nobis) under control conditions and in the presence

of Fc-GPVI-nt (100 µg/ml) or equimolar concentrations of control Fc. PDGF release is normalised to the manufacturer's standard probe.

PDGF release as an indicator for release of endogenous transmitters from alpha granules of platelets was also blunted after collagen stimulation. (Fig 11c)

Example 15: Effect of Fc-GPVI-nt on bleeding time from human whole blood in vitro. In vitro bleeding time was determined with an PFA-100 device (Dade-Behring). 800 µl of human whole blood was injected in the PFA-100 device. Bleeding time was measured with ADP/collagen and epinephrine/collagen coated measuring cells according to the manufacturer's instructions.

There was no significant prolongation of bleeding time in vitro (PFA-100 device) with increasing concentrations of Fc-GPVI-nt after different agonist stimulations. In contrast, therapeutically relevant concentrations of ReoPro maximally prolonged bleeding time in the PFA-100 device (Fig 12)

Example 16: Effect of soluble GPVI on platelet adhesion to immobilized collagen under flow. Human platelets were isolated from ADC-anticoagulated whole blood as described (18). Washed platelets were resuspended in Tyrodes-HEPES buffer (2.5 mmol/l HEPES, 150 mmol/l NaCl, 12 mmol/l NaHCO₃, 2.5 mmol/l KCl, 1 mmol/l MgCl₂, 2 mmol/l CaCl₂, 5.5 mmol D-Glucose, 1 mg/ml BSA, pH 7.4) to obtain a platelet count of 2x10⁸ cells/ml. Adhesion of platelets to plates coated with immobilized collagen was determined in a parallel plate flow chamber in the presence of 200 µg/ml Fc-GPVI-nt or control Fc.

GPVI plays a crucial role in the process of platelet recruitment to immobilized collagen *in vitro* (22). We determined the effect of Fc-GPVI-nt on adhesion of human platelets to immobilized collagen under shear conditions *in vitro*. As reported by others earlier (23), platelets adhered firmly to immobilized collagen at both low (500sec⁻¹) and high (1000sec⁻¹) shear rates forming thrombi (Fig. 13). Soluble Fc-GPVI-nt, but not control Fc lacking the external GPVI domain, significantly attenuated platelet adhesion on immobilized collagen by 37 and 44 % at shear rates of 500sec⁻¹ and 1000sec⁻¹, respectively (Fig. 13). Inhibition was specific since Fc-GPVI-nt did not affect platelet adhesion to immobilized vWF.

Example 17: Determination of Fc-GPVI-nt plasma concentrations was carried out with an IMMUNO-TEK ELISA system for the quantitative determination of human IgG (ZeptoMetrix Corporation; Cat # 0801182). Specific peroxidase conjugated goat anti-human IgG antibodies against the Fc part of the Fc-GPVI-nt are used (Dianova). After several washing steps with PBS-T according to the manufacturer's specifications peroxidase substrate (BM Blue POD, Roche) is added and measured at the characteristic 450 nm wavelength in an ELISA assay reader (Tecan Sunrise). The Fc-GPVI-nt concentration is quantified by comparison to an internal human IgG standard. Fc-GPVI-nt showed favourable in vivo pharmacokinetics. After single intraperitoneal injection in mice high plasma levels were measurable after 24 hours and the half life of the fusion protein exceeded 96 hours (Fig 14a). Repeated intraperitoneal injection was leading to blood accumulation of the fusion protein (Fig 14b) suggesting favourable kinetics for long term application for the treatment of chronic diseases. After single intravenous injection of Fc-GPVI-nt with increasing doses, dose-dependent plasma concentrations of Fc-GPVI-nt were detectable over 5 to 60 minutes up to 14 hours (Fig 14c).

Example 18: Preparation of murine platelets for intravital fluorescence microscopy. Murine platelets were isolated from whole blood and labeled with 5-carboxyfluorescein diacetate succinimidyl ester (DCF) as reported earlier(19). The DCF-labeled platelet suspension was adjusted to a final concentration of 200×10^6 platelets/250 μ l. Adhesion of murine platelets was assessed prior to and after carotid injury by *in vivo* video microscopy, as described below.

Example 19: Carotid ligation and assessment of platelet adhesion and aggregation by intravital microscopy. Platelet recruitment following endothelial denudation was performed as reported earlier (3). In brief, wild type C57BL6/J mice were anesthetized by intraperitoneal injection of a solution of midazolame (5 mg/kg body weight, Ratiopharm, Ulm, Germany), medetomidine (0.5 mg/kg body weight, Pfizer, Karlsruhe, Germany), and fentanyl (0.05 mg/kg body weight, CuraMed Pharma GmbH, Munich, Germany). Where indicated, Fc-GPVI-nt (1 or 2 mg/kg body weight) or control Fc in an amount equimolar to 2mg/kg Fc-GPVI-nt was administered intravenously. Thereafter, endothelial denudation was induced near the carotid bifurcation by vigorous ligation for 5 min. Following induction of vascular injury fluorescent platelets (200×10^6 /250 μ l) were infused intravenously via polyethylene catheters (Portex, Hythe, England) implanted into the right jugular vein. The fluorescent platelets were visualized *in situ* by *in vivo* video microscopy of the right common carotid

artery using a Zeiss Axiotech microscope (20 x water immersion objective, W 20x/0.5, Zeiss) with a 100W HBO mercury lamp for epi-illumination. All video-taped images were evaluated using a computer-assisted image analysis program (Cap Image 7.4, Dr. Zeintl, Heidelberg, Germany (19;20)). Tethered platelets were defined as *all* cells establishing initial contact with the vessel wall, followed by slow surface translocation (at a velocity significantly lower than the centerline velocity) or by firm adhesion; their numbers are given as cells per mm² endothelial surface. The number of adherent platelets was assessed by counting the cells that did not move or detach from the endothelial surface within 10 seconds. The number of platelet aggregates at the site of vascular injury was also quantified and is presented per mm². In addition, the total thrombus area was assessed using Cap Image 7.4.

Example 20: Scanning electron microscopy. Following intravital videofluorescence microscopy, the carotid artery was perfused with PBS (37°C) for 1 min in three animals per group, followed by perfusion fixation with phosphate-buffered glutaraldehyde (1% vol/vol). The carotid artery was excised, opened longitudinally, further fixed by immersion in 1% PBS-buffered glutaraldehyde for 12 hours, dehydrated in ethanol, and processed by critical point drying with CO₂. Subsequently, the carotid artery specimens were oriented with the lumen exposed, mounted with carbon paint, sputter coated with platinum, and examined using a field emission scanning electron microscope (JSM-6300F, Jeol Ltd., Tokyo, Japan).

Example 21: Assessment of in vivo Fc-GPVI-nt binding by immunohistochemistry. Carotid arteries obtained from mice treated with Fc-GPVI-nt were shock frozen and embedded in cryoblocks (medite, Medizintechnik GmbH, Burgdorf, Germany). The binding of Fc-GPVI-nt to the endothelium and subendothelium was determined on 5µm cryostat sections, stained with peroxidase-conjugated goat anti-human IgG antibody Fcγ fragment specific (109-035-098; Dianova, Hamburg, Germany). Carotid arteries obtained from Fc-treated mice served as controls.

Example 22: Effect of soluble GPVI on platelet counts, bleeding time and platelet adhesion in vivo.

Animals were treated with 2 mg/kg or 4 mg/kg Fc-GPVI-nt or equimolar doses of control Fc lacking the external GPVI domain. Infusion of Fc-GPVI-nt or control Fc even at the highest dose of 4mg/kg had not significant effects on peripheral platelet counts. Moreover, the Fc-GPVI-nt fusion protein, did not induce any significant prolongation of tail bleeding times compared to

control animals (Fig. 15a). The absolute bleeding times were 1.9 ± 0.9 in PBS treated mice and 2.9 ± 1.9 min and 4.6 ± 0.6 min in mice treated with 2mg/kg or 4mg/kg Fc-GPVI-nt. In contrast, bleeding times were prolonged considerably (42.6 ± 21.6) in Integrilin -treated animals (0.2 mg per kg IV).

The effects of Fc-GPVI-nt on platelet recruitment in a mouse model of carotid injury may be studied using intravital fluorescence microscopy. Animals were treated with 1 mg/kg or 2 mg/kg Fc-GPVI-nt or an equimolar amount of control Fc lacking the external GPVI domain as described above. After infusion of Fc-GPVI-nt or control Fc endothelial denudation of the mouse carotid artery was induced by vigorous ligation as reported previously (3). Ligation of the carotid artery consistently caused complete loss of the endothelial cell layer. Platelet adhesion was directly visualized and quantified using *in vivo* fluorescence microscopy (19;20) (Fig. 15 d). In control (Fc-treated) mice numerous platelets were tethered to the vascular wall within the first minutes after endothelial denudation (12.026 ± 1.115 tethered platelets/mm²). Platelets establishing contact with the subendothelium exhibited initially a slow surface translocation, which is frequently followed by subsequent firm platelet adhesion and platelet aggregation (5.494 ± 874 adherent platelets/mm² and 114 ± 17 platelet thrombi/mm²). In contrast, in the presence of Fc-GPVI-nt platelet recruitment to the site of vascular injury was dramatically attenuated. Platelet tethering was reduced by 65 and 71 % compared to Fc-treated animals following pretreatment with 1mg/kg or 2mg/kg Fc-GPVI-nt ($P < 0.05$ vs. control). In parallel, firm platelet adhesion was reduced in a dose-dependent manner (by 49 and 65 % following administration of 1mg/kg or 2mg/kg Fc-GPVI-nt, respectively; $P < 0.05$ vs. control). Likewise, aggregation of adherent platelets was virtually absent in animals treated with 2mg/kg Fc-GPVI-nt fusion protein ($P < 0.05$ vs. control Fc, Fig. 15b - d). Scanning electron microscopy also clearly demonstrated that platelet adhesion and aggregation following endothelial denudation of the common carotid artery were virtually absent in Fc-GPVI-nt treated, but not in Fc-pretreated mice (Fig. 15e). To confirm the presence of Fc-GPVI-nt at the site of injury, the carotid arteries were excised following *in vivo* microscopy and processed further for immunohistochemistry using peroxidase-conjugated goat anti-human IgG antibodies. In Fc-GPVI-nt-treated mice Fc-GPVI-nt was detected on at the luminal aspect of the site of vascular damage (Fig. 15 f). Together, these data demonstrate that Fc-GPVI-nt specifically binds to sites of vascular injury *in vivo* and prevents subsequent platelet recruitment.

Effect of soluble GPVI on atherosclerosis. 4 weeks old apoE $-/-$ mice (The Jackson Laboratory) consumed a 0.25% cholesterol diet (Harlan Research diets) for 6 weeks. After 2 weeks 4 apoE $-/-$ mice were injected with Fc-GPVI-nt 200 μ g per mouse twice weekly with continuous cholesterol diet. 4 apoE $-/-$ mice with the similar protocol were injected with the control Fc protein (200 μ g) twice weekly and served as control mice. For assessment of plaque formation the animals were killed and the vascular tree was carefully dissected from the animals. The whole preparations of the aortae and carotides were flushed with 0.9 % sodium chloride and fixed. The complete vascular preparation was stained with SUDAN III red to assess plaque formation and viewed under a microscope. Treatment of atherosclerosis prone apoE $-/-$ knockout mice with Fc-GPVI-nt over 4 weeks significantly attenuated atheroprogession. (Fig 16).

Example 23: FACS measurement of CD61 and CD32 surface expression on platelets from diabetic patients. Human citrate blood was collected from 111 patients suffering from diabetes or from 363 non-diabetic patients. Platelet rich plasma (PRP) was generated after centrifugation and washing procedures (PBS 1x, pH 7.2) with 2000 rpm at 4°C and resuspension. Anti CD61 and anti CD32 antibodies labelled with the fluorophor peroxidase (Immunotech) were added or or the anti monoclonal anti-GPVI antibody 4C9 labelled with FITC. FACS measurement was performed with an Becton Dickenson FACScalibur device. Surface expression was quantified by fluorescence. Correlation of CD32 fluorescence and 4C9 fluorescence was calculated with the correlation coefficient $r=0.516$.

Statistical Analysis. Comparisons between group means were performed using Mann-Whitney Rank Sum Test. Data represent mean $\pm$ s.e.m.. A value of $P < 0.05$ was regarded as significant.

Reference List

1. Baumgartner, H.R. 1977. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin-digested subendothelium. *Thromb Haemost* 37:1-16.
2. Clemetson, K.J. and Clemetson, J.M. 2001. Platelet collagen receptors. *Thromb. Haemost.* 86:189-197.
3. Massberg, S., Gawaz, M., Gruner, S., Schulte, V., Konrad, I., Zohlnhöfer, D., Heinzmann, U., and Nieswandt, B. 2003. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. *J. Exp. Med.* 197:41-49.
4. Moroi, M., Jung, S.M., Okuma, M., and Shinmyozu, K. 1989. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. *J Clin. Invest* 84:1440-1445.
5. Clemetson, J.M., Polgar, J., Magnenat, E., Wells, T.N., and Clemetson, K.J. 1999. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to Fc α R and the natural killer receptors. *J Biol. Chem.* 274:29019-29024.
6. Jandrot-Perrus, M., Busfield, S., Lagrue, A.H., Xiong, X., Debili, N., Chickering, T., Le Couedic, J.P., Goodearl, A., Dussault, B., Fraser, C. *et al.* 2000. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. *Blood* 96:1798-1807.
7. Gibbins, J.M., Okuma, M., Farndale, R., Barnes, M., and Watson, S.P. 1997. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. *FEBS Lett.* 413:255-259.
8. Zheng, Y.M., Liu, C., Chen, H., Locke, D., Ryan, J.C., and Kahn, M.L. 2001. Expression of the platelet receptor GPVI confers signaling via the Fc receptor gamma -chain in response to the snake venom convulxin but not to collagen. *J Biol. Chem.* 276:12999-13006.

9. Suzuki-Inoue,K., Tulasne,D., Shen,Y., Bori-Sanz,T., Inoue,O., Jung,S.M., Moroi,M., Andrews,R.K., Berndt,M.C., and Watson,S.P. 2002. Association of Fyn and Lyn with the proline rich domain of GPVI regulates intracellular signalling. *J Biol.Chem.*
10. Barnes,M.J., Knight,C.G., and Farndale,R.W. 1998. The collagen-platelet interaction. *Curr.Opin.Hematol.* 5:314-320.
11. Falet,H., Barkalow,K.L., Pivniouk,V.I., Barnes,M.J., Geha,R.S., and Hartwig,J.H. 2000. Roles of SLP-76, phosphoinositide 3-kinase, and gelsolin in the platelet shape changes initiated by the collagen receptor GPVI/FcR gamma-chain complex. *Blood* 96:3786-3792.
12. Pasquet,J.M., Gross,B., Quek,L., Asazuma,N., Zhang,W., Sommers,C.L., Schweighoffer,E., Tybulewicz,V., Judd,B., Lee,J.R. et al. 1999. LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI. *Mol.Cell Biol.* 19:8326-8334.
13. Berlanga,O., Tulasne,D., Bori,T., Snell,D.C., Miura,Y., Jung,S., Moroi,M., Frampton,J., and Watson,S.P. 2002. The Fc receptor gamma-chain is necessary and sufficient to initiate signalling through glycoprotein VI in transfected cells by the snake C- type lectin, convulxin. *Eur.J.Biochem.* 269:2951-2960.
14. Sugiyama,T., Okuma,M., Ushikubi,F., Sensaki,S., Kanaji,K., and Uchino,H. 1987. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. *Blood* 69:1712-1720.
15. Sugiyama,T., Ishibashi,T., and Okuma,M. 1993. Functional role of the antigen recognized by an antiplatelet antibody specific for a putative collagen receptor in platelet-collagen interaction. *Int.J.Hematol.* 58:99-104.
16. Schulte,V., Snell,D., Bergmeier,W., Zirngibl,H., Watson,S.P., and Nieswandt,B. 2001. Evidence for two distinct epitopes within collagen for activation of murine platelets. *J Biol.Chem.* 276:364-368.
17. Kremmer,E., Kranz,B.R., Hille,A., Klein,K., Eulitz,M., Hoffmann-Fezer,G., Feiden,W., Herrmann,K., Delecluse,H.J., Delsol,G. et al. 1995. Rat monoclonal antibodies

differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B). *Virology* 208:336-342.

18. Dickfeld,T., Lengyel,E., May,A.E., Massberg,S., Brand,K., Page,S., Thielen,C., Langenbrink,K., and Gawaz,M. 2001. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. *Cardiovasc.Res.* 49:189-199.
19. Massberg,S., Enders,G., Leiderer,R., Eisenmenger,S., Vestweber,D., Krombach,F., and Messmer,K. 1998. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. *Blood* 92:507-515.
20. Massberg,S., Enders,G., Matos,F.C., Tomic,L.I., Leiderer,R., Eisenmenger,S., Messmer,K., and Krombach,F. 1999. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. *Blood* 94:3829-3838.
21. Miura,Y., Takahashi,T., Jung,S.M., and Moroi,M. 2002. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. *J.Biol.Chem.* 277:46197-46204.
22. Chen,H., Locke,D., Liu,Y., Liu,C., and Kahn,M.L. 2002. The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. *J Biol.Chem.* 277:3011-3019.
23. Savage,B., Almus-Jacobs,F., and Ruggeri,Z.M. 1998. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. *Cell* 94:657-666.
24. van Zanten,G.H., de Graaf,S., Slootweg,P.J., Heijnen,H.F., Connolly,T.M., de Groot,P.G., and Sixma,J.J. 1994. Increased platelet deposition on atherosclerotic coronary arteries. *J Clin.Invest* 93:615-632.

25. Baumgartner,H.R., Muggli,R., Tschopp,T.B., and Turitto,V.T. 1976. Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. *Thromb.Haemost.* 35:124-138.
27. Jandrot-Perrus,M., Lagrue,A.H., Okuma,M., and Bon,C. 1997. Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin alpha2beta1. *J Biol.Chem.* 272:27035-27041.
28. Rekhter,M.D. 1999. Collagen synthesis in atherosclerosis: too much and not enough. *Cardiovasc.Res.* 41:376-384.
29. Ruggeri,Z.M. 1997. Mechanisms initiating platelet thrombus formation. *Thromb.Haemost.* 78:611-616.
30. Goto,S., Ikeda,Y., Saldivar,E., and Ruggeri,Z.M. 1998. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. *J.Clin.Invest.* 101:479-486.
31. Sixma,J.J., van Zanten,G.H., Banga,J.D., Nieuwenhuls,H.K., and de Groot,P.G. 1995. Platelet adhesion. *Semin.Hematol* 32:89-98.
32. Nieswandt,B., Schulte,V., Bergmeier,W., Mokhtari-Nejad,R., Rackebrandt,K., Cazenave,J.P., Ohlmann,P., Gachet,C., and Zirngibl,H. 2001. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. *J Exp Med* 193:459-469.
33. Lincoff,A.M., Califf,R.M., and Topol,E.J. 2000. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. *J.Am.Coll.Cardiol.* 35:1103-1115.
34. Neumann,F.J. and Schömig, A. 1998. Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. *Semin.Interv.Cardiol.* 3:81-90.
35. Bertrand,M.E., Rupprecht,H.J., Urban,P., Gershlick,A.H., and Investigators,f. 2000. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after

coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). *Circulation* 102:624-629.

36. Foster,R.H. and Wiseman,L.R. 1998. Abciximab. An updated review of its use in ischaemic heart disease. *Drugs* 56:629-665.
37. Arai, M., Yamamoto,N., Moroi,M., Akamatsu,N., Fukutake,K., and Tanoue,K. 1995. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. *Br.J Haematol.* 89:124-130.

SEQUENCE LISTING

<110> ProCorde GmbH

<120> Immunoadhesin comprising a glycoprotein VI domain

<130> PCT-12286

<140> PCT/EP03/05929

<141> 2003-06-05

<150> EP 02 012 742

<151> 2002-06-07

<160> 9

<170> PatentIn version 3.1

<210> 1

<211> 504

<212> PRT

<213> Artificial Sequence

<220>

<223> fusion protein

<400> 1

Met Ser Pro Ser Pro Thr Ala Leu Phe Cys Leu Gly Leu Cys Leu Gly
1 5 10 15

Arg Val Pro Ala Gln Ser Gly Pro Leu Pro Lys Pro Ser Leu Gln Ala
20 25 30

Leu Pro Ser Ser Leu Val Pro Leu Glu Lys Pro Val Thr Leu Arg Cys
35 40 45

Gln Gly Pro Pro Gly Val Asp Leu Tyr Arg Leu Glu Lys Leu Ser Ser
50 55 60

Ser Arg Tyr Gln Asp Gln Ala Val Leu Phe Ile Pro Ala Met Lys Arg
65 70 75 80

Ser Leu Ala Gly Arg Tyr Arg Cys Ser Tyr Gln Asn Gly Ser Leu Trp
85 90 95

Ser Leu Pro Ser Asp Gln Leu Glu Leu Val Ala Thr Gly Val Phe Ala
100 105 110

Lys Pro Ser Leu Ser Ala Gln Pro Gly Pro Ala Val Ser Ser Gly Gly
115 120 125

Asp Val Thr Leu Gln Cys Gln Thr Arg Tyr Gly Phe Asp Gln Phe Ala
130 135 140

Leu Tyr Lys Glu Gly Asp Pro Ala Pro Tyr Lys Asn Pro Glu Arg Trp
145 150 155 160

Tyr	Arg	Ala	Ser	Phe	Pro	Ile	Ile	Thr	Val	Thr	Ala	Ala	His	Ser	Gly			
				165					170					175				
Thr	Tyr	Arg	Cys	Tyr	Ser	Phe	Ser	Ser	Arg	Asp	Pro	Tyr	Leu	Trp	Ser			
			180					185					190					
Ala	Pro	Ser	Asp	Pro	Leu	Glu	Leu	Val	Val	Thr	Gly	Thr	Ser	Val	Thr			
		195					200					205						
Pro	Ser	Arg	Leu	Pro	Thr	Glu	Pro	Pro	Ser	Ser	Val	Ala	Glu	Phe	Ser			
	210					215					220							
Glu	Ala	Thr	Ala	Glu	Leu	Thr	Val	Ser	Phe	Thr	Asn	Lys	Val	Phe	Thr			
225					230					235					240			
Thr	Glu	Thr	Ser	Arg	Ser	Ile	Thr	Thr	Ser	Pro	Lys	Glu	Ser	Asp	Ser			
				245					250					255				
Pro	Ala	Gly	Pro	Ala	Arg	Gln	Tyr	Tyr	Thr	Lys	Gly	Asn	Gly	Gly	Arg			
			260					265					270					
Glu	Ser	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala			
		275					280					285						
Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro			
	290					295					300							
Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val			
305					310					315					320			
Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val			
				325					330					335				
Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln			
			340					345					350					
Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln			
		355					360					365						
Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala			
	370					375					380							
Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro			
385					390				395						400			
Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr			
				405					410					415				
Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser			
			420					425					430					
Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr			
	435						440					445						
Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr			
	450					455					460							
Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe			
465					470					475					480			

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 485 490 495

Ser Leu Ser Leu Ser Pro Gly Lys
 500

<210> 2

<211> 1515

<212> DNA

<213> Artificial Sequence

<220>

<223> DNA coding for the fusion protein of SEQ ID No: 1

<400> 2

atgtctccat ccccgaccgc cctcttctgt cttgggctgt gtctggggcg tgtgccagcg	60
cagagtggac cgctcccca ggcctccctc caggctctgc ccagctccct ggtgcccctg	120
gagaagccag tgaccctccg gtgccaggga cctccggggc tggacctgta ccgcctggag	180
aagctgagtt ccagcaggta ccaggatcag gcagtcctct tcatcccggc catgaagaga	240
agtctggctg gacgctaccg ctgctcctac cagaacggaa gcctctggtc cctgcccagc	300
gaccagctgg agctcgttgc cacgggagtt ttgccaaac cctcgctctc agcccagccc	360
ggcccggcgg tgcgtcagg aggggacgta accctacagt gtcagactcg gtatggcttt	420
gaccaatttg ctctgtacaa ggaaggggac cctgcgcctt acaagaatcc cgagagatgg	480
taccgggcta gtttcccat catcacggtg accgccgccc acagcggaac ctaccgatgc	540
tacagcttct ccagcaggga ccatacctg tggtcggccc ccagcgaccc cctggagctt	600
gtggtcacag gaacctctgt gacccccagc cggttaccaa cagaaccacc ttctctcgta	660
gcagaattct cagaagccac cgctgaactg accgtctcat tcacaaacaa agtccttcaca	720
actgagactt ctaggagtat caccaccagt ccaaaggagt cagactctcc agctggtcct	780
gcccgccagt actacaccaa gggcaacggc ggccgcgagt ccaaattctg tgacaaaact	840
cacacatgcc caccgtgccc agcacctgaa ctcttggggg gaccgtcagt cttcctcttc	900
cccccaaac ccaaggacac cctcatgac tcccggaccc ctgagggtcac atgcgtgggtg	960
gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag	1020
gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc	1080
agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc	1140
tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc	1200
cgagagccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc	1260
agcctgacct gcctgggtcaa aggccttctat ccagcgaca tcgccgtgga gtgggagagc	1320

aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380
 ttcttctctt acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440
 tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg 1500
 tctccgggta aatga 1515

<210> 3
 <211> 490
 <212> PRT
 <213> artificial

<400> 3
 Met Ser Pro Ser Pro Thr Ala Leu Phe Cys Leu Gly Leu Cys Leu Gly
 1 5 10 15
 Arg Val Pro Ala Gln Ser Gly Pro Leu Pro Lys Pro Ser Leu Gln Ala
 20 25 30
 Leu Pro Ser Ser Leu Val Pro Leu Glu Lys Pro Val Thr Leu Arg Cys
 35 40 45
 Gln Gly Pro Pro Gly Val Asp Leu Tyr Arg Leu Glu Lys Leu Ser Ser
 50 55 60
 Ser Arg Tyr Gln Asp Gln Ala Val Leu Phe Ile Pro Ala Met Lys Arg
 65 70 75 80
 Ser Leu Ala Gly Arg Tyr Arg Cys Ser Tyr Gln Asn Gly Ser Leu Trp
 85 90 95
 Ser Leu Pro Ser Asp Gln Leu Glu Leu Val Ala Thr Gly Val Phe Ala
 100 105 110
 Lys Pro Ser Leu Ser Ala Gln Pro Gly Pro Ala Val Ser Ser Gly Gly
 115 120 125
 Asp Val Thr Leu Gln Cys Gln Thr Arg Tyr Gly Phe Asp Gln Phe Ala
 130 135 140
 Leu Tyr Lys Glu Gly Asp Pro Ala Pro Tyr Lys Asn Pro Glu Arg Trp
 145 150 155 160
 Tyr Arg Ala Ser Phe Pro Ile Ile Thr Val Thr Ala Ala His Ser Gly
 165 170 175
 Thr Tyr Arg Cys Tyr Ser Phe Ser Ser Arg Asp Pro Tyr Leu Trp Ser
 180 185 190
 Ala Pro Ser Asp Pro Leu Glu Leu Val Val Thr Gly Thr Ser Val Thr
 195 200 205
 Pro Ser Arg Leu Pro Thr Glu Pro Pro Ser Ser Val Ala Glu Phe Ser
 210 215 220
 Glu Ala Thr Ala Glu Leu Thr Val Ser Phe Thr Asn Lys Val Phe Thr
 225 230 235 240

Thr Glu Thr Ser Arg Ser Ile Thr Thr Ser Pro Lys Glu Ser Asp Ser
 245 250 255
 Pro Ala Gly Pro Ala Arg Gln Tyr Tyr Thr Lys Gly Asn Gly Gly Arg
 260 265 270
 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 275 280 285
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 290 295 300
 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 305 310 315 320
 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 325 330 335
 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 340 345 350
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 355 360 365
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 370 375 380
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 385 390 395 400
 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 405 410 415
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 420 425 430
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 435 440 445
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 450 455 460
 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 465 470 475 480
 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 485 490

<210> 4
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR primer

<400> 4
 cgcggggcgg ccgcgagtc aaatcttggtg acaaaac

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 5
gcgggaagct ttcatttacc cggagacagg gag 33

<210> 6
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 6
gcggggagat ctaccaccat gtctccatcc cggacc 36

<210> 7
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 7
cgcggggcg cgcgcgttgc ccttggtgta gtac 34

<210> 8
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 8
cgcggggcg cgcgccagca cctgaactcc tg 32

<210> 9
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 9
cgcggggata tctcatttac ccggagacag ggag 34

76766-61

54

CLAIMS:

1. A fusion protein comprising:

a) a glycoprotein VI (GPVI) portion selected from an extracellular domain of GPVI and a variant thereof that
5 is functional for binding to collagen; and

b) an Fc portion selected from an Fc domain of an immunoglobulin and a functional conservative variant thereof,

the GPVI portion and the Fc portion being fused via a linker having the amino acid sequence Gly-Gly-Arg.

10 2. The fusion protein according to claim 1, wherein the Fc domain thereof is an IgG Fc domain.

3. The fusion protein according to claim 1, which comprises the amino acid sequence of SEQ ID NO:1.

4. The fusion protein according to claim 1 or
15 claim 2, wherein the extracellular domain of GPVI is human.

5. The fusion protein according to any one of claims 1 to 4, wherein the Fc domain is human.

6. The fusion protein according to any one of claims 1 to 5, wherein the functional conservative variant
20 of the Fc domain is functional for enabling the fusion protein to be secreted from a cell in a form functional for binding to collagen.

7. The fusion protein according to any one of claims 1 to 6, which is glycosylated at one or several amino
25 acids.

8. The fusion protein according to any one of claims 1 to 7, which is a homodimeric fusion protein.

76766-61

55

9. The fusion protein according to claim 8, wherein the two monomers of the homodimeric fusion protein are covalently linked.

10. The fusion protein according to claim 8 or
5 claim 9, which is fluorescence labelled.

11. A nucleic acid molecule comprising a sequence selected from the following group:

a) the nucleic acid sequence of SEQ ID NO:2 or a variant thereof that codes for the same polypeptide
10 according to the degeneracy of the genetic code:

b) a nucleic acid sequence coding for a polypeptide that has at least 70% sequence homology to the polypeptide encoded by SEQ ID NO:2, wherein the nucleic acid sequence encodes a polypeptide comprising, from its
15 N-terminus to its C-terminus, an extracellular domain of GPVI or a variant thereof functional for binding to collagen, a linker having the amino acid sequence Gly-Gly-Arg, and an Fc domain or a functional conservative variant thereof functional for enabling a protein encoded by the
20 nucleic acid to be secreted from a cell in a form functional for binding to collagen; and

c) a nucleic acid sequence coding for a polypeptide of at least 300 amino acids and having, in the 5' to 3' direction, a first segment encoding at least 100
25 amino acids comprising an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen, a second segment which encodes the amino acid sequence Gly-Gly-Arg, and a third segment encoding at least 200 amino acids functional as an Fc domain for enabling a protein
30 encoded by the nucleic acid to be secreted from a cell in a form functional for binding to collagen.

76766-61

56

12. The nucleic acid according to claim 11, comprising the sequence of SEQ ID NO:2.

13. The nucleic acid according to claim 11, wherein in the nucleic acid sequence defined in (a) or (b), bases at
5 positions corresponding to bases 1 to 807 of SEQ ID NO:2 encode the extracellular domain of GPVI.

14. The nucleic acid according to claim 11, wherein in the nucleic acid sequence defined in (a) or (b), bases at
10 positions corresponding to bases 817 to 1515 of SEQ ID NO:2 encode an Fc domain of an IgG immunoglobulin.

15. A protein encoded by the nucleic acid according to any one of claims 11 to 14.

16. An anti-atherosclerotic agent for the treatment or prevention of atherosclerosis, said agent comprising two
15 polypeptide chains encoded by the nucleic acid of any one of claims 11 to 14, each having a hinge region connected to the hinge region of the other by inter-chain disulfide bonds.

17. A vector comprising the nucleic acid according to any one of claims 11 to 14.

20 18. A cell expressing the fusion protein according to any one of claims 1 to 10.

19. A pharmaceutical composition comprising an immunoadhesin and a pharmaceutically acceptable carrier, wherein said immunoadhesin is a homodimeric fusion protein
25 comprising an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen; and an Fc domain of an immunoglobulin or a functional conservative part thereof, the extracellular domain or variant thereof and the Fc domain or functional conservative part thereof

76766-61

57

being fused via a linker, said linker having the amino acid sequence Gly-Gly-Arg.

20. The pharmaceutical composition according to claim 19, wherein the immunoadhesin is a homodimer of the polypeptide of SEQ ID NO:2.

21. The pharmaceutical composition according to claim 19 or claim 20, which is an intravenous preparation.

22. Use, of the homodimeric fusion protein as defined in claim 8 or claim 9, or of the protein according to claim 15 when in homodimeric form, for the manufacture of a medicament to treat or prevent atherosclerosis in a patient.

23. The use according to claim 22, wherein the medicament is for the prevention of atheroprogession.

24. Use, of the homodimeric fusion protein as defined in claim 8 or claim 9 or of the protein according to claim 15 when in homodimeric form, for the manufacture of a medicament for the prevention of intraarterial thrombosis in a patient.

25. The use according to claim 24, wherein the patient suffers from an acute coronary or carotid syndrome and has active intraarterial lesions.

26. The use according to any one of claims 22 to 25, wherein the medicament is for the treatment of atherosclerotic complications of diabetes.

27. Use, of the homodimeric fusion protein as defined in claim 8 or claim 9 or of the protein according to claim 15 when in homodimeric form, for the manufacture of a medicament for the treatment or prevention of myocardial infarction and/or cerebral stroke.

76766-61

58

28. The use according to any one of claims 22 to 27, wherein the medicament is for administration orally, subcutaneously, intraperitoneally or intravenously.

29. The use according to any one of claims 22 to 28,
5 wherein the medicament is in a dosage form containing 0.5 to 6.0 mg/kg of the fusion protein.

30. Use, of the homodimeric fusion protein as defined in claim 8 or claim 9 or of the protein according to claim 15 when in homodimeric form, for screening for
10 inhibitors of GPVI binding to collagen *in vitro*.

31. The use according to claim 30, wherein the homodimeric fusion protein is fluorescence-labelled.

32. A method of *in vitro* screening for inhibitors of binding of glycoprotein VI to collagen, comprising:

15 (i) providing a surface that exposes collagen;

(ii) contacting a portion of said surface with the fusion protein of claim 8 or claim 9 or the protein according to claim 15 when in homodimeric form under predetermined conditions that allow binding of said fusion
20 protein to said surface;

(iii) contacting another portion of said surface with said fusion protein in the presence of a test compound under conditions as in step (ii);

(iv) determining the amount of said fusion protein
25 bound to said surface in the absence and in the presence of said test compound;

(v) identifying the test compound as an inhibitor if binding of said fusion protein to said surface is less in

76766-61

59

the presence of said test compound as compared to the absence of the test compound; and

(vi) optionally determining the functional effect of said inhibitor on platelet aggregation and/or platelet
5 actuation.

33. Use, of the homodimeric fusion protein as defined in claim 8 or claim 9 or of the protein according to claim 15 when in homodimeric form, for *in vitro* screening for inhibitors of GPVI mediated adhesion of platelets to
10 active intravascular lesions.

34. A method of producing a monoclonal antibody from a non-human mammal comprising using the homodimeric fusion protein as defined in claim 8 or claim 9 or a protein according to claim 15 when in homodimeric form as an
15 immunogen.

35. Use of the homodimeric fusion protein as defined in claim 8 or claim 9 for the treatment or prevention of atherosclerosis.

36. The use according to claim 35 which is for the
20 prevention of atheroproggression.

37. Use of the homodimeric fusion protein as defined in claim 8 or claim 9 for the prevention of intraarterial thrombosis in a patient.

38. The use according to claim 37, wherein the patient
25 suffers from an acute coronary or carotid syndrome and has active intraarterial lesions.

39. The use according to any one of claims 35 to 38, which is for the treatment of atherosclerotic complications of diabetes.

76766-61

60

40. Use of the homodimeric fusion protein as defined in claim 8 or claim 9 for the treatment or prevention of myocardial infarction and/or cerebral stroke.

41. The use according to any one of claims 35 to 40,
5 wherein the homodimeric fusion protein is for administration orally, subcutaneously, intraperitoneally or intravenously.

42. The use according to any one of claims 35 to 41,
wherein the homodimeric fusion protein is in a dosage form
containing 0.5 to 6.0 mg/kg of the homodimeric fusion
10 protein.

43. Use of the protein according to claim 15 when in homodimeric form for the treatment or prevention of atherosclerosis.

44. The use according to claim 43 which is for the
15 prevention of atheroproggression.

45. Use of the protein according to claim 15 when in homodimeric form for the prevention of intraarterial thrombosis in a patient.

46. The use according to claim 45, wherein the patient
20 suffers from an acute coronary or carotid syndrome and has active intraarterial lesions.

47. The use according to any one of claims 43 to 46,
which is for the treatment of atherosclerotic complications of diabetes.

25 48. Use of the protein according to claim 15 when in homodimeric form for the treatment or prevention of myocardial infarction and/or cerebral stroke.

76766-61

61

49. The use according to any one of claims 43 to 48, wherein said protein is for administration orally, subcutaneously, intraperitoneally or intravenously.

50. The use according to any one of claims 43 to 49,
5 wherein the protein is in a dosage form containing 0.5 to 6.0 mg/kg of the protein.

51. The pharmaceutical composition according to claim 19 or claim 20 for use in the treatment or prevention of atherosclerosis.

10 52. The pharmaceutical composition according to claim 51 which is for the prevention of atheroprogession.

53. The pharmaceutical composition according to claim 19 or claim 20 for use in the prevention of intraarterial thrombosis in a patient.

15 54. The pharmaceutical composition according to claim 53, wherein the patient suffers from an acute coronary or carotid syndrome and has active intraarterial lesions.




55. The pharmaceutical composition according to any one of claims 51 to 54, which is for the treatment of
20 atherosclerotic complications of diabetes.



56. The pharmaceutical composition according to claim 19 or claim 20 for use in the treatment or prevention of myocardial infarction and/or cerebral stroke.

1a


Control

Vascular Injury


*1b*

1c


2a




2b





2c




d



3a



Control JAQ1-treated



3b

Control





GPVI-deficient




5/27



3c




3d



f



3e







Fig. 4

7/27



8/27




Fig. 6

1 MSPSP TALFC LGLCLGRVPA QSGPLPKPSL QALPSSLVPL EKPVTLRCOG
51 PPGVDLYRLE KLSSSRYQDQ AVLFIPAMKR SLAGRYRCSY QNGSLWSLPS
101 DQLELVATGV FAKPSLSAQP GPAVSSGGDV TLQCQTRYGF DQFALYKEGD
151 PAPYKNPERW YRASFPITV TAAHSGTYRC YSFSSRDPYL WSAPSDPLEL
201 VVTGTSVTPS RLPTEPPSSV AEFSEATAEL TVSFTNKVFT TETSR SITTS
251 PKESDSPAGP ARQYYTKGNG GRESKSCDKT HTCPCCPAPE LLGGPSVFLF
301 PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE
351 EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP
401 REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
451 TPPVLDS DGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL
501 SPGK*



Fig. 7

10/27

1 ATGTCTCCAT CCCCACCGC CCTCTTCTGT CTTGGGCTGT GTCTGGGGCG
51 TGTGCCAGCG CAGAGTGGAC CGTCCCCAA GCCCTCCCTC CAGGCTCTGC
101 CCAGCTCCCT GGTGCCCCTG GAGAAGCCAG TGACCCTCCG GTGCCAGGGA
151 CCTCCGGGCG TGGACCTGTA CCGCCTGGAG AAGCTGAGTT CCAGCAGGTA
201 CCAGGATCAG GCAGTCCTCT TCATCCCGGC CATGAAGAGA AGTCTGGCTG
251 GACGCTACCG CTGCTCCTAC CAGAACGGAA GCCTCTGGTC CCTGCCCAGC
301 GACCAGCTGG AGCTCGTTGC CACGGGAGTT TTTGCCAAAC CCTCGCTCTC
351 AGCCCAGCCC GGCCCGGCGG TGTCGTCAGG AGGGGACGTA ACCCTACAGT
401 GTCAGACTCG GTATGGCTTT GACCAATTTG CTCTGTACAA GGAAGGGGAC
451 CCTGCGCCCT ACAAGAATCC CGAGAGATGG TACCGGGCTA GTTTCCCCAT
501 CATCACGGTG ACGCCGCCC ACAGCGGAAC CTACCGATGC TACAGCTTCT
551 CCAGCAGGGA CCCATACCTG TGGTCGGCCC CCAGCGACCC CCTGGAGCTT
601 GTGGTCACAG GAACCTCTGT GACCCCCAGC CGGTTACCAA CAGAACCACC
651 TTCCTCGGTA GCAGAATTCT CAGAAGCCAC CGCTGAACTG ACCGTCTCAT
701 TCACAAACAA AGTCTTCACA ACTGAGACTT CTAGGAGTAT CACCACCAGT
751 CCAAAGGAGT CAGACTCTCC AGCTGGTCCT GCCCGCCAGT ACTACACCAA
801 GGGCAACGGC GGCCGCGAGT CCAAATCTTG TGACAAAAC CACACATGCC
851 CACCGTGCCC AGCACCTGAA CTCCTGGGGG GACCGTCAGT CTCCTCTTC
901 CCCCCAAAAC CCAAGGACAC CCTCATGATC TCCCGGACCC CTGAGGTCAC
951 ATGCGTGGTG GTGGACGTGA GCCACGAAGA CCCTGAGGTC AAGTTCAACT
1001 GGTACGTGGA CGGCGTGGAG GTGCATAATG CCAAGACAAA GCCGCGGGAG
1051 GAGCAGTACA ACAGCACGTA CCGTGTGGTC AGCGTCCTCA CCGTCCTGCA
1101 CCAGGACTGG CTGAATGGCA AGGAGTACAA GTGCAAGGTC TCCAACAAAG
1151 CCCTCCCAGC CCCCATCGAG AAAACCATCT CCAAAGCCAA AGGGCAGCCC
1201 CGAGAGCCAC AGGTGTACAC CCTGCCCCCA TCCCGGGATG AGCTGACCAA
1251 GAACCAGGTC AGCCTGACCT GCCTGGTCAA AGGCTTCTAT CCCAGCGACA
1301 TCGCCGTGGA GTGGGAGAGC AATGGGCAGC CGGAGAACAA CTACAAGACC
1351 ACGCCTCCCG TGCTGGACTC CGACGGCTCC TTCTTCCTCT ACAGCAAGCT
1401 CACCGTGGAC AAGAGCAGGT GGCAGCAGGG GAACGTCTTC TCATGCTCCG
1451 TGATGCATGA GGCTCTGCAC AACCCTACA CGCAGAAGAG CCTCTCCCTG
1501 TCTCCGGGTA AATGA

Fig. 8



Figure 9



250 —
150 —
100 —
75 —
50 —
37 —
25 —

Coomassie Stain

12/27

b**c**








Figure 10

15/27

Figure 11 Platelet aggregation**a****b**


C


Figure 12

Figure 13







Figure 14

a

Fc-GPVI-nt Pharmacokinetic single dose

**b**

Fc-GPVI-nt Pharmacokinetic repeated dose



C

IV pharmacokinetic in mice







Figure 15


a




b**c**

d



e


Fc



Fc-GPVI-nt

f

Fc



Fc-GPVI-nt



Figure 16

Fc-GPVI-nt




Fc




Figure 17

CD61 Expression on Human Platelets



CD 32 Receptor Expression on human Platelets



Korrelation CD32-GPVI


 $p < 0,0001$ $r = 0,516$

Figure 18

MSPSPTALFCLGLCLGRVPAQSGPLPKPSLQALPSSLVPLEKPVTLRCQGPPGVDLYRLEKLSSSRYQDQ
AVLFIPAMKRSLAGRYRCSYQNGSLWSLPSDQLELVATGVFAKPSLSAQPGPAVSSGGDVTLCQTRYG
FDQFALYKEGDPAPYKNPERWYRASFPITVTAHSGTYRCYSFSSRDPYLWSAPSDPLELVVTGTSVTP
SRLPTEPPSSVAEFSEATAELTVSFTNKVFTTETSRSTTSPKESDSPAGPARQYYTKGN ~~GG~~PAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSQVMHEALHNHYTQKSLSLSPG
K